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Abstract. Over a decade, laser trabeculoplasty has evolved from being a novel new treatment to 
one that is a commonly accepted intervention in the management of open-angle glaucoma. 
Despite its widespread use, however, there are still many unanswered questions about laser 
traberuloplastv, including its mechanism of action and the ideal treatment parameters. In this 
review, we wiil discuss the history of the technique, the clinical experience, and some of the 
experimental studies that have been conducted to answer the questions regarding its mechanism 
of action. (Surv Ophthalmol 35:407-428, 1991) 
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Argon laser treatment of the trabecular mesh- 
work was described in the United States by 
Worthen and Wickham”’ in 1973. The modified 
technique later described by Wise and Witter17’ in 
1979 gained acceptance and popularity within a 
short time and now plays an important role in the 
treatment of advanced open-angle glaucoma. Yet, 
despite widespread use, many basic questions con- 
cerning the treatment parameters, mechanism of 
action, and efricacy of the treatment remain unan- 
swered. ‘l-his will review the large body of literature 
concerning argon laser trabeculoplasty and will also 
attempt to of‘fer a reasonable treatment approach to 
the patient who may benefit from argon laser tra- 
beculoplasty (ALT). 
I. Historical Perspective 
Laser technology first became available in the 
early 1960s. Its application to the anterior chamber 
angle structures solely for the purpose of reducing 
intraocular pressure (IOP) was not reported in the 
American literature until 1973.17’ In that year, 
Krasnov described a “micropuncture” technique 
utilizing a Q-switched ruby laser in ten chronic 
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open-angle glaucoma patients in Russia.“’ A tempo- 
rary reduction of IOP in all subjects, accompanied 
by improved outflow facilities was noted in this ear- 
ly report.“g This technique, termed laser trabeculot- 
omy, attempted to provide a direct aqueous path- 
way into Schlemm’s canal. 
Worthen and Wickham described the cellular 
and histopathological changes associated with ar- 
gon laser applications of varying intensity in mon- 
keys. I”? The following year, their human clinical 
studies, which were the first conducted and pub- 
lished in the United States, drew attention to the 
potential use of laser treatment in open-angle glau- 
coma. Although the power levels and duration set- 
tings were significantly higher than those employed 
in present-day techniques,“’ an average IOP re- 
duction of 9.6 % 8.9 mm Hg in 20 patients three 
weeks after the treatment was noted. Four patients, 
who were followed up for one year, demonstrated 
an average decrease in IOP of 11.3 mm Hg. EX- 
tended follow-up of Worthen and Wickham’s pa- 
tients suggested that conventional surgery could be 
delayed for three months to three years following 
laser, which was a desirable treatment outcome in 
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itself. The results prompted these investigators to 
propose that “argon laser trabeculotomy” should 
be tried before resorting to conventional glaucoma 
surgery. I59 Ticho and Zauberman,‘3g using the ar- 
gon laser, noted improvement in the outflow facili- 
ties of glaucomatous eyes after laser treatment. Oth- 
er investigators441’“J reported success with argon 
laser treatment. However, enthusiasm for these 
techniques was dampened by the adverse effects 
(most significantly, increased IOP) of laser treat- 
ment to the trabecular meshwork reported in 
animals 33,17? 
Interest in argon laser treatment in glaucoma 
management increased after a report by Wise and 
Witter in 1979.17’ These investigators used less en- 
ergy and reported moderate pressure reduction 
and few complications. One-hundred laser burns at 
a power level ranging from 1000 to 1500 mW were 
placed over 360” of trabecular meshwork. The 
burns, which were 50 F in size and 0.1 set in dura- 
tion, produced an average pressure reduction of 
10.29 mm Hg at three months in 41 patients with 
primary open angle glaucoma. They postulated 
that localized burns in the trabecular meshwork 
caused shrinkage of collagen in the tissue, resulting 
in a pulling or tightening of the adjacent tissues. 
This was thought to result in widening of the tra- 
becular pores and a reduction in outflow resistance. 
Published reports in 1981 of this technique, now 
known as ALT, by Schwartz et al,“” Wilensky and 
Jampol,‘6S Sutton et a1,13’ and Pohjanpeltox” con- 
firmed the initial success reported by Wise.“’ 
II. Theories Regarding the Mechanism 
of Action of Argon Laser Trabeculoplasty 
The effects of ALT on aqueous outflow as well as 
inflow have been studied. Many of the earliest in- 
vestigators demonstrated that improvement of ton- 
ographic outflow facility occurred following laser 
treatment to the angle structures.6”‘“g Clinical stud- 
ies that utilized the Wise technique (ALT) also re- 
vealed increased outflow facility.2’v”6,’ ‘*,‘96*‘63,‘74 Uti- 
lizing fluorophotometry, Brubaker and Liesegang 
found that aqueous flow, cornea1 permeability to 
fluorescein, and the blood-aqueous exchange coef- 
ficient did not differ significantly in 17 treated eyes 
when compared to controls.‘3 Other investigators 
noted a temporary breakdown in the blood-aque- 
ous barrier following laser trabeculoplasty; howev- 
er, this finding is unlikely to have any longterm 
significance. *’ Thus, it was established that an in- 
crease in the facility of aqueous outflow was the 
most significant determinant which modified intra- 
ocular pressure following ALT. 
The question remains - by what mechanism is 
aqueous outflow improved? Some of the various 
Fig. 1. Gonioscopic cross-sectional view of angle struc- 
ture. A. Collapsed trabecular meshwork in a glaucoma- 
tous eye that has received laser treatment. Note the par- 
tially closed trabecular spaces (Tl). [Cornea (E), 
Schwalbe’s line (G), Schlemm’s canal (C), Scleral spur (S), 
Sclera (F), Uveal meshwork (U), Iris (I). B. Laser burns 
(L), which were applied along the anterior edge of the 
pigmented band (P), have resulted in tissue shrinkage 
and contraction. This causes the trabecular spaces (T2) to 
open. (Reprinted from Wise JB16’: Highlights of Ophthd- 
mology, 30th Anniversary Edition, Volume I, courtesy of 
JB Wise, B.F. Boyd, and S. Gordon.) 
theories proposed have been discussed in detail by 
Van Buskirk.14” Initially, Wise and Witter17’ pro- 
posed that ALT worked by reversing a pathological 
laxity of the trabecular tissues, which resulted in a 
collapse of the meshwork, subsequently diminish- 
ing aqueous outflow facility. One could envision mi- 
croscars causing tissue retraction around the entire 
trabecular circumference, which would literally 
pull the meshwork open between the scars (Fig. 1). 
This “mechanical” theory, perhaps the most popu- 
lar explanation of ALT’s mechanism of action, has 
been both mathematically (geometrically) and intu- 
itively discussed in detail (Fig. 2).‘“7*‘6y Histopatho- 
logical examination of laser-treated meshwork sam- 
ples obtained from human subjects revealed early 
necrosis of cells and disruption of trabecular beams. 
There was no evidence of penetrating holes into 
Schlemm’s canal.‘0’.‘6” However, there was shrink- 
age of certain collagenous elements seen in some 
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specimens. 
Since there is no animal model for primary open- 
angle glaucoma or ALT, it is difficult to confirm the 
mechanical theory in the laboratory. However, it is 
interesting to note the studies of laser-treated mon- 
key trabecular meshwork by Melamed et al.74 These 
investigators noted widened intertrabecular spaces 
with juxtacanalicular tissue herniated into Schlemm’s 
canal when the specimens were examined histologi- 
cally. In a later study by this group, cationized ferri- 
tin was infused into the eyes of previously laser- 
treated cynomolgus monkeys. Light microscopy 
revealed that this compound, which may have acted 
as a tracer, had selectively shifted around the la- 
sered areas and was noted in large quantities in the 
juxtacanalicular tissues, in vacuoles, and within 
Schlemm’s canal.7’ These results must be interpret- 
ed with caution, because the distribution of cation- 
ized ferritin may be charge-dependent and not sim- 
ply flow-dependent. Furthermore, this study was 
performed on a nonhuman, nonglaucomatous mod- 
el and cannot be directly extrapolated to a pro- 
posed mechanism of action in humans. 
Another theory of the mechanism by which ALT 
lowers IOP centers on the possibility of laser-in- 
duced physiologic changes in the trabecular cells. 
Van Buskirk et al first reported differences in glyco- 
saminoglycan turnover, cell density, and cellular 
biosynthesis measured by ““S-sulfate incorporation 
in laser-treated autopsy eyes.‘“” Melamed et al also 
reported that laser-treated meshwork cells ap- 
peared to be more actively phagocytic and suggest- 
ed that a cellular change had been promoted in the 
meshwork.” Recently, increased trabecular cell di- 
vision following ALT has been demonstrated using 
tritiated thymidine uptake in a human organ cul- 
ture system. “.” Cell division at sites distant to the 
laser burns and migration of cells into the burn 
areas were documented histopathologically. Other 
researchers have found an increase in fibronectin, 
an important component of extracellular matrix, 
following laser treatment of feline meshwork.“j 
In summary, despite questions regarding wheth- 
er the exact cellular mechanism of action is purely 
mechanical, cellular, or a combination of both, vir- 
tually all investigators are convinced that ALT 
causes an enhancement of egress of fluid via the 
trabecular outflow system resulting in lowered IOP. 
III. Technique 
Over the years, investigators have modified their 
laser parameters in the hope of further maximizing 
therapeutic effects while minimizing adverse re- 
sults. The importance of careful technique was 
shown by Khan et al, who noted definite differences 
between a group of patients treated with ALT by 
B 
c 
Fig. 2. A geometric model of laser trabeculoplasty. A. 
Saggital section through the anterior globe, which high- 
lights the trabecular meshwork band. B. For illustrative 
purposes, halfof the untreated trabecular meshwork ring 
is shown with a diameter D. C. Following treatment, tis- 
sue contraction causes the entire ring to become smaller 
with the diameter reduced to D2. Notice that the trabecu- 
lar spaces (T2) have become more open, which allows for 
improved outflow facility. (Reprinted from Wise JB’““: 
~ighi~gh~~ of Op}lth~l~no~~~, 30th Anniversary Edition. 
Volume 1. courtesy of JB Wise, B.F. Boyd, and S. Gor- 
don.) 
resident physicians and a group treated by more 
experienced attending physicians.,i” A more suc- 
cessful outcome was found in patients treated by the 
more experienced attending staff, suggesting that 
the application of identical laser parameters alone 
was not a guarantee of similar outcomes. 
A. PROPORTION OF THE ANGLE TREATED 
The minimum amount of angle treatment re- 
quired in a given patient to obtain adequate pres- 
sure response remains uncertain. Treating only 90 
of the angle, Wilensky and Weinreb reported a 
mean decrease in IOP of 6.85 mm Hg one month 
following treatment in 21 eyes.‘“” In 16 eyes that 
underwent consecutive 90” of laser treatment, IOP 
dropped an additional 3.56 mm Hg on average. 
Schwartz et al, in disagreement with these results, 
found that treatment limited to 90” of the angle 
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resulted in only a 10% pressure drop on average 
compared to a 28% decrease in patients receiving 
180” or more of treatment.‘lg 
In a prospective study, Weinreb et al demonstrat- 
ed that treatment of half of the angle (1807 with 50 
burns resulted in pressure reduction comparable to 
that achieved with treatment of the full angle (360”) 
with 100 burns, while causing much less acute post- 
treatment IOP elevation. 155 In another study of var- 
ious types of glaucoma patients, 62% of patients 
treated over only 180” of angle were adequately 
controlled without requiring the second 180” to be 
treated.53 Other reports also reported no significant 
differences between groups receiving full circum- 
ference and half-circumference treatment in a pro- 
spective study.45*6g Of interest in this one report, 
however, was the observation that eyes with the 
largest pressure decreases (greater than 12 mm Hg) 
were most numerous in the 360” treatment group. 
Elsas, in contrast, in a nonconcurrent comparative 
study reported a higher degree of successful IOP 
control with 100 spots than with 50 spots.74 Other 
investigators who have also corroborated the clini- 
cal efhcacy of 180” treatment include Fazio et alz6 
and Eguchi et al. ” Wilensky and Weinreb have sug- 
gested, however, that full treatment was more likely 
to result in persistent pressure reductions.15’ 
B. LOCATION OF BURNS 
The optimal location for placement of the laser 
burns has been addressed in several studies. Popu- 
lar sites of burn placement include just along the 
anterior border of the pigmented meshwork and 
more posteriorly, directly on the pigmented mesh- 
work, but some have treated as far posteriorly as the 
scleral spur.” Schwartz et al studied several groups 
of patients having laser treatment to either posteri- 
or or anterior meshwork. They reported adequate 
pressure reduction regardless of treatment site.“” 
Higgins similarly found the best response when ei- 
ther the posterior or anterior aspects of the mesh- 
work were treated, although a good response was 
noted in all locations.4g In contradistinction, Eguchi 
et al noted much less success with treatment over 
the anterior part of the trabecular band.” Most re- 
cently, Rouhiainen et al, reported that burn loca- 
tion did not affect outcome to any significant ex- 
tent.“’ 
An associated question is whether a laser surgeon 
can accurately place burns on specific angle struc- 
tures. Starita et a113’ correlated clinical impression 
at the time ofALT with histopathological analysis of 
tissue specimens obtained at surgery. They report- 
ed that accurate placement of the laser spots was 
attained in 11 of 13 patients.13’ (The relationship of 
burn placement to particular complications will be 
Fig. 3. Reason for proper laser focus. This magnified sec- 
tion of trabeculum shows the “aerial point of focus” [the 
50~ size circle at (A)] of the laser beam (L) and the view- 
er’s eyepiece focal point [solid lines (B)] both converging 
on the same point on the trabeculum. This results in a 
proper 50 TV, burn size on the trabeculum with a simulta- 
neous clear, focused view of the trabeculum through the 
eyepieces. [Cornea (E), Schlemm’s canal (D), Scleral spur 
(S).] (Reprinted from Wise JB 16’. Highlights of Ophthalmol- . 
ogy, 30th Anniversary Edition, Volume I, courtesy of JB 
Wise, B.F. Boyd, and S. Gordon.) 
discussed in Section VII.) 
C. ENERGY DENSITY 
Energy is determined by a combination of dura- 
tion, power, and spot size. Blondeau et al studied 
the possibility that increasing duration of the laser 
burn, while individually adjusting the power set- 
ting, might favorably affect response.’ Their result 
revealed no statistically significant difference in the 
pressure drop following burns of either 0.1 or 0.2 
set duration. Most clinicians presently utilize the 
0.1 sec. spot duration, as initially described by 
Wise.“’ 
As previously noted, histopathological work by 
Starita et al suggested direct correlations among 
the amount of power administered, degree of pig- 
mentation present, and the histological changes 
obtained.“” Since power level was shown to be a 
relevant and controllable variable, there was a ques- 
tion as to what power setting was required to obtain 
an optimal IOP response from ALT. Rouhiainen 
and Terasvirta were able to demonstrate a relation- 
ship between laser power, total energy delivered, 
and response obtained. Those eyes receiving laser 
power equal to or above 500mW responded with an 
IOP reduction; thus the minimum power level re- 
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quired was delineated.‘04 In a later study, Rou- 
hiainen et al found that varying the power levels 
(500~800mW) or the visible laser effect did not af- 
fect IOP response. lo7 Others, however, do recom- 
mend a visible tissue response as the endpoint for 
successful treatment.‘“4 Wilensky reported using 
a uniform power level irrespective of visible re- 
sponse, and has obtained results comparable to 
those who vary their setting according to tissue 
response.“” 
Spot size is a frequently overlooked variable that 
can adversely affect the outcome of the treatment. 
One of the most vocal proponents of controlling 
spot size is Wise. He reported a wide range in the 
size of the burns created by several different lasers 
that had been set to deliver the same spot size.“’ On 
a theoretical basis he has proposed that larger spots 
affect the angle in less than an ideal way, causing 
undesirable scarring and adverse architectural 
modification (Figs. 3 and 4). To avoid this, Wise 
recommended adjustment of the objective settings 
of the delivery system so that the focused point of 
the aiming beam, as well as that of the slit-lamp, 
were identical. This would prevent defocused laser 
energy from creating too large a spot, which could 
cause diffuse damage to the meshwork. Also, it is 
worth noting that a doubling of spot size reduces 
power density by 75%, which may have its own dele- 
terious effect on outcome. We would encourage 
careful attention to aiming beam focus to avoid as- 
tigmatic or unfocused spots which could increase 
the chance of failure. 
Recently, Ritch described a new lens, which is 
designed to improve the view of the superior angle, 
while also reducing the spot size to approximately 
70% of its original.“” The use of this lens may be 
helpful in minimizing spot size regardless of which 
laser is used. Unlike defocused larger spots, burns 
smaller than 50~ have been associated with satisfac- 
tory results by some investigators.“” 
D. LASER WAVELENGTH 
Most studies of ALT have used argon lasers emit- 
ting blue-green light; however, other wavelengths 
have been evaulated. Smith compared the effect of 
argon blue-green and green lasers in 100 patients 
with POAG. He found no difference in pressure 
response, post-operative course, or complication 
rate following blue-green or green laser treat- 
ment.lT6 This finding was corroborated by Ma- 
kabe.7” 
Utilizing the krypton red and yellow laser in 15 
patients, Spurny and Lederer noted adequate pres- 
sure reduction following laser trabeculoplasty.“” In 
direct contradistinction, however, Makabe found 
that krypton red laser had no sustained effect on 
Fig. 4. Principal cause of improper laser burn size. The 
surgeon sees the trabeculum clearly in focus [depicted by 
solid lines (B), which come to a focused point on the 
trabeculum], but the point of focus of the laser beam (L) is 
in front of the trabeculum. Adjusted as such, the laser 
beam diverges beyond this “aerial point of focus” (A) to 
create an improper, larger than 50~ size [larger circle at 
(C) on the trabeclum]. The goal is to adjust the viewing 
pieces so that they focus at the same location (on the 
trabeculum) as the laser beam 50~ focal point, as shown 
in Fig. 3. Then, as the surgeon focuses the eyepieces on 
the trabeculum, the 50~ laser spot will fall or’ the trabecu- 
lum. [Cornea (E), Schelmm’s canal (D), Scleral spur (S). 
(Reprinted from Wise JB ’ fin: Highlights of Ophthalmology, 
30th Anniversary Edition, Volume I, couktesy ofJB Wise, 
B.F. Boyd, and S. Gordon.) 
Experience with the Q-switched laser has also 
been described. Bonney et al” and Gaasterland and 
Bonney”” demonstrated the ability of the Q- 
switched ruby laser to create holds in the meshwork 
of monkeys. As discussed earlier, this was previous- 
ly reported by Krasnov in 1973 to be somewhat 
successful in humans with glaucoma.‘” More recent- 
ly, Robin and Pollack also proposed using a Q- 
switch ruby laser to avoid excessive thermal tissue 
destruction from argon blue-green light.!” (The Q- 
switched laser has the feature of delivering high 
energy levels in short pulses, leading to mechanical 
instead of thermal effects.) In four eyes with secon- 
dary glaucoma that were poor candidates for ALT, 
Robin and Pollack reported an average IOP drop of 
15 (& 9) mm Hg with a follow-up of 2-15 months. 
Although extrapolation of results to typical POAG 
patients was discouraged, their pilot study suggest- 
ed the possibility of an alternative to argon laser 
with some theoretical advantages. 
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Neodymium:YAG (Nd:YAG) lasers also have 
been used to treat the trabecular meshwork. Two 
different types of laser energy have been studied. In 
1985, Melamed et al reported limited success fol- 
lowing attempted trabecular puncture with the Q- 
switched Nd:YAG laser.75 Robin et al and Epstein et 
al, each using a different technique, later applied Q- 
switched Nd:YAG laser energy to the trabecular 
meshwork of humans. Robin and coworkers ap- 
plied 10 spots of I OmJ, approximately 4” apart and 
reported a pressure drop of 9 (k 7) mm Hg at an 
average follow-up of five months.” Tonographic 
values improved from 0.07 ? 0.04 mm Hg to 0.17 
2 0.2 ml/min/mm Hg. Pressure spikes were seen in 
eight eyes, transient bleeding in six, and posterior 
displacement of the iris root in four. The authors 
proposed formation of minicyclodialyses and/or in- 
creased uveoscleral outflow as mechanisms of ac- 
tion. One-year follow-up of these patients found 
that 46% maintained an IOP of less than 22 mm 
Hg.ls Of particular note was a successful outcome in 
five of six aphakic eyes. A more recent study of 18 
eyes treated in a similar manner reported minimal 
success ‘a however. These authors found less pres- 7 
sure response and more complications, including 
pressure elevation that necessitated emergency fil- 
tration surgery in one eye. 
Epstein et al utilized a technique in which 3-6 
superimposed spots of 2-6 mJ of energy were ap- 
plied at 4-6 sites in ten eyes with open angle glauco- 
ma (exfoliation, POAG, or juvenile).‘5 They report- 
ed a small pressure reduction of diminishing 
magnitude in four of six POAG eyes over a follow- 
up of 2-l 1 months. In this group, one eye suffered 
a severe pressure rise that necessitated urgent sur- 
gery. This led the authors to suggest avoiding the 
technique altogether in POAG. Treatment of the 
eyes with “juvenile” glaucoma produced more satis- 
factory results, and a possible future role for the 
technique in juvenile or congenital-type angles may 
exist. 
The other group of studies with Nd:YAG lasers 
attempted to perform conventional laser trabeculo- 
plasty using 10 msec pulses of neodymium laser 
energy. “1,“2 Treatment results were reported to be 
comparable to those achieved with argon energy. 
IV. Results 
In discussing treatment results, the success rate 
can be defined in many ways - e.g., 1) a pressure 
drop of greater than a certain percent; 2) final pres- 
sure of less than a certain level with or without 
medications; or 3) absence of glaucomatous disc 
and field progression. In general, an acceptable re- 
sult for most clinicians is a level of intraocular pres- 
sure that abates the progression of the disease and 
thus necessitates no further surgical intervention. 
Because success is often defined differently in each 
paper, those readers requiring specifics should con- 
sult each reference for details. A more detailed dis- 
cussion of the outcomes in specific glaucoma enti- 
ties is covered in section VI of this review. 
A. INTRAOCULAR PRESSURE 
The degree of IOP reduction is largely depend- 
ent upon a multitude of patient factors. Therefore, 
a more detailed discussion of IOP reduction will 
follow later. At this point, the comments will con- 
centrate on diurnal curves, postoperative anti- 
glaucoma medication reduction, and duration of 
the IOP reduction. 
I. Effect on Diurnal Curves 
Several investigators have previously reported 
the presence of large diurnal pressure swings and 
high peak pressures in glaucoma patients com- 
pared to controls. ‘g~2’~57 Greenidge et a14’ specifically 
looked at the effect of ALT on the diurnal curves of 
glaucoma subjects before and eight weeks after 
treatment. Although pressure spikes were not total- 
ly eliminated, a beneficial effect on the diurnal 
curve was found. Mean peak pressure, presumed to 
be of pathophysiologic importance in causing disc 
damage, was found to decrease by 25%. lmprove- 
ment in both peak pressures and pressure ranges 
was reported in five patients who did not demon- 
strate any apparent laser response on a single ofice 
reading (“the index pressure”). This suggests that 
ALT can also offer a positive therapeutic effect to 
some patients who do not demonstrate an obvious 
pressure response on routine office visits. 
2. Reduction in Antiglaucoma Medications 
Perhaps another measure of success is the ability 
of the physician to remove some or all medications 
from a therapeutic regimen. In general, ALT has 
not allowed discontinuation of all antiglaucomatous 
medications, although some reduction in the num- 
ber of medications has been reported.“0*5Y,‘2ff Thom- 
as et al, for example, were able to taper medications 
in 26.1% of eyes with primary open angle glaucoma 
(POAG) and in 41.2% of eyes with exfoliative glau- 
coma.“” Similarly, Horns et al reported that medi- 
cations could be reduced in 28.7% ofeyes with open 
angle glaucoma.5” Although Pollack and Robin not- 
ed that 82% of patients with POAG required some 
medications, 64.2% of patients who previously had 
required carbonic anhydrase inhibitors and 57% of 
those who had required miotics were satisfactorily 
controlled without these medications after ALT.8Y 
Follow-up of at least 18 months was obtained in this 
group. Previous work by these authors had re- 
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vealed similar results.“x ’ _ 1 herefore, ALT appears to 
be “curative” in only a minority of patients in that 
some or most of the previously used medication(s) 
are usually still necessary. 
3. Duration of Effect 
The duration of IOP reduction following ALT 
has been examined by several authors utilizing 
longterm follow-up studies. In interpreting any of 
these data, the reader must ask several questions. 1) 
Do the results include those patients who have 
failed AL?‘ and gone on to conventional surgery or 
cyclodestructive therapy ? If these patients have 
been removed from the data but are not statistically 
accounted f‘or, as with Kaplan-Meier life table anal- 
ysis, the success rate of the technique will appear 
better than it really is. 2) How is success defined? As 
previously discussed, the definition of success may 
be too lenient or too demanding. This could distort 
the conclusions, either exaggerating success or em- 
phasizing failure . 3) What types of patients are be- 
ing reported? Do they represent referral patients 
with more severe disease who are, thus, more likely 
to fail ALT, or are they representative of the aver- 
age mix seen in clinical practice? 4) What type of 
glaucoma is being treated? The term “open-angle” 
can be loosely used to include several variants, such 
as exfoliation and pigmentary, which have different 
success rates and outcomes. With these questions in 
mind, the reader should be able to carefully analyze 
any data and reach his or her own conclusions as to 
how ALT might provide longterm impact in clinical 
practice. 
In 19X 1, Wise published the results of longterm 
follow-up after ALT in 150 eyes.“‘” All were fol- 
lowed for at least six months after treatment, and 
some had been followed for up to four years. The 
mean IOP reduction in 150 eyes was 12.26 mm Hg 
at six months. This remained fairly constant through 
30 months, when 37 eyes had a mean IOP drop of 
10.49 mm Hg. At 4X months, 11 eyes were found to 
have a mean pressure drop of 13.29 mm Hg. Of the 
150 e!‘es, only 9% needed subsequent filtering sur- 
gery. Overall, the number and type of medications 
did not change great]). ‘l‘he results of a smaller 
number of’eyes suggested that the success rate was 
also quite high and long-lasting among blacks and 
native American Indians. On the basis of this study. 
Wise reiterated his previous conclusions that AL? 
was an efficacious and safe therapeutic technique 
that avoided the morbidity of conventional filtra- 
tion surgery. Pohjanpelto also reported fairly stable 
pressure reductions at follow-up periods of 18 to 42 
months.” 
Schwartz anct coworkers, however, were much 
less optimistic in interpreting results from theit 
longterm study in 1985. I”’ The average reduction 
in IOP fell from 9.7 mm Hg at two months to 4.9 
mm Hg at five years. Kaplan-Meier analysis of the 
data suggested that black patients failed at a shorter 
interval than did white patients, a conclusion far 
different from that reached by Wise. In another 
study, Grinich et al reported the effect of ALT on 
intraocular pressure in 58 eyes over a three-year 
follow-up.‘” Success was defined as an IOP of less 
than 22 mm Hg with no further surgical or laser 
intervention. Using life-table analysis, cumulative 
success rates fell from 79% (112 eyes) at one year to 
69% (85 eyes) at two years and finally 59% (5X eyes) 
at three years. 
In a study by Shingleton et al”’ of 118 eyes of 93 
patients with POAG, exfoliation, or aphakia, Kap- 
lan-Meier analysis predicted a 52% chance of satis- 
factory control at four years. Success was defined in 
terms of intraocular pressure, stability of visual field 
and optic nerve, and avoidance of surgery. Failure 
rate seemed highest (23%) within the first year fol- 
lowing treatment, with failure occurring at a rate of 
7-10% per year thereafter. 
In what is probably the longest reported follow- 
up to date, Wise recently reported the first ten-yea] 
results in his series.“” In this report, the proportion 
of eyes maintaining an IOP of less than 2 1 mm Hg 
was 79% at one year, 63% at four years, and only 
45% (76 eyes) at seven years. Interestingly, this in- 
creased to 70% at ten years in a smaller group (10 
eyes). Wise suggested that the lessened effect at year 
seven was due to patient selection factors that were 
as yet undefined. In the 37 treated eyes of’24 pa- 
tients who later died, only one eye had required 
filtration surgery during the patient’s lifetime. 
Thus, ALT did avoid the morbidity of conventional 
surgery in this group of individuals. The “surgical 
rate” as a whole was reported as 92% at one year 
and 63% at seven years. Of prognostic significance, 
Wise found that those eyes having the most severe 
disease (cup to disc ratio > 0.9) had a 5 1% rate of 
undergoing surgery as opposed to those with less 
severe damage (cup to disc ratio ~0.9) who had a 
16% glaucoma surgery rate. Overall, 30% of 1 10 
eyes followed to year six required surgery despite 
previous ALT. 
Again, Wise found that a small number of eyes of 
non-white patients did not appear to fare any worse 
than the entire group of patients. Since a large 
number of patients were able to avoid glaucoma 
surgery throughout their lifetimes. Wise concluded 
that ALI‘ did indeed do more than merely delay 
surgery. However, the results of this longterm 
study do suggest a loss of effect with time. 
In the only tongterm report following “low dose” 
ALT, Barnes and Wilensky reported that I 1 of 16 
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eyes that had received 25 to 50 burns over 90” of the 
angle, demonstrated a significant and persistent 
IOP drop.” Follow-up ranged from 1 to 4.2 years 
and did not include two eyes that demonstrated an 
average pressure rise of 2 mm Hg. This report must 
be interpreted with the understanding that life-ta- 
ble analysis was not performed and that some pa- 
tients did not return for follow-up. The results indi- 
cate, however, that low dose treatment can be a 
viable longterm option in some patients. 
Another measure of the longterm efficacy of ALT 
has been described by Gilbert et al.“” These authors 
examined the rate of filtration surgery in a resi- 
dency program immediately following the intro- 
duction of ALT in the clinic and several years later. 
In the pre-laser period from 1978 through 1981, 
filtration surgeries were performed, compared to 
only one in 1982 and 18 in 1984, most of which 
were done in patients who had previous ALT. 
In summary, it appears that ALT is not a cure or 
permanent success in all patients. ALT does, how- 
ever, appear to control IOP for extended periods of 
time in many patients and in some may eliminate 
the need for filtering surgery, with its attendant 
risks and potential complications. 
B. PERIMETRY 
Several investigators have studied the effect of 
ALT on visual field test results. Holmin and Krakau 
reported that successful laser trabeculoplasty failed 
to halt progressive visual field loss over a one-year 
period in 15 patients.“” Heijl and Bengtsson could 
not demonstrate any correlation between pressure 
reduction and computerized field improvement in 
42 eyes tested both before and one month after 
ALT.l” Similarly, Holmin and Bauer studied 23 
eyes and were unable to demonstrate any improve- 
ment in the visual field.5’ In a study of 19 patients, 
Schultz et al examined visual fields obtained at in- 
tervals of 1, 4, 8, and 12 months following ALT. 
They utilized one-way analysis of variance and 
trend analysis, finding that six patients showed vi- 
sual field improvements, eight showed no change, 
and five showed progressive worsening (Octopus 
program 32).“” Six of their original 25 patients 
were excluded because of glaucoma progression 
that necessitated surgery or changes in medication. 
Lieberman et al found a worsening of visual fields in 
11% of eyes with chronic open angle glaucoma 
(6/53) despite IOP reduction following ALT. The 
authors attributed this finding to a continuation of 
the damage in these already diseased eyes.“” In con- 
trast, Spaeth, using intricate analyses of patients 
who had Octopus perimetry three months and one 
year following ALT, found a direct correlation be- 
tween intraocular pressure reduction and visual 
field improvement.“’ Traverso et al also reported 
some improvement in Octopus fields following 
ALT-induced pressure reduction.‘4’4 
V. Patient Factors 
Ophthalmologists have observed that ALT may 
be more successful in some individuals than others. 
There are several patient factors that may be of 
importance in predicting a successful outcome in 
any particular laser candidate. 
A. AGE 
Over the years, a general impression has devel- 
oped that younger patients have less of a response 
to ALT than their older counterparts. Safran et al 
conducted a retrospective study comparing pa- 
tients younger than and older than 40 years who 
had POAG uncontrolled by maximally tolerated 
medical treatment (range, 14-37 years; 46-85 
years). lo9 Only 7% of eyes in the older group re- 
quired surgical intervention after laser compared 
to 60% in the younger individuals. In addition, the 
older patients appeared to have a statistically great- 
er decrease in pressure (12 + 6 mm Hg) in re- 
sponse to ALT than those less than 40 years old (5 
* 6 mm Hg). The diagnosis of POAG in a younger 
population is complicated by the possibility that 
some or all of these individuals may actually repre- 
sent a juvenile variant of POAG, having a prognosis 
and natural disease history different than the typi- 
cal POAG seen in older patients. Regardless, the 
poorer response to ALT in younger patients has 
also been reported by others and should be borne 
in mind when counselling the younger laser candi- 
date."0,4',l"6 
B. RACE 
There are a number of reasons why black patients 
would be ideal candidates for ALT. One of the most 
salient concerns is the significantly lower success 
rate following filtering surgery in this group than in 
white patients. ‘lo As such, avoidance of convention- 
al surgery would be most desirable. Following ALT 
in a predominantly black group of patients, 
Schwartz et al reported a 97% success rate with an 
18-month follow-up.“” Krupin et al, retrospectively 
examined the results of ALT in 68 black and 42 
white POAG patients over one- and two-year peri- 
ods (only 13 patients had not returned for follow- 
up at two years), found no statistical difference in 
the response seen between black and white pa- 
tients.64 Similar results have also been reported in 
other studies,“‘and ALT in an Asian population has 
also provided equivalent responses and success 
rate. '25 With longer follow-up of previously studied 
individuals, however, Schwartz et al found that 
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ALT did fail to a greater degree in black patients 
than in whites.“” In light of these conflicting find- 
ings, further studies are necessary to settle this con- 
troversy. 
C. PIGMENTATION 
Pigmentation of the trabecular meshwork has 
been proposed in numerous papers to be a possible 
factor in successful pressure responses. Degree of 
pigmentation may correlate with the post-laser 
pressure drop by one of several mechanisms: 1) 
ability to obtain good laser focus on a more pig- 
mented trabecular meshwork; 2) absorption of la- 
ser energy by pigment, permitting more efficient 
conversion of laser energy to heat in the desired 
location; and 3) removal of pigment, which may 
play a pathogenic role in causing outflow compro- 
mise.” Although several authors have acknowl- 
edged some advantage to the presence of pig- 
ment, x,4’.‘0i.‘4” agreement with this observation is 
not universal.“,“” In pigmentary dispersion and ex- 
foliation syndromes, assessment of the pigment fac- 
tor is complicated by the fact that the ALT response 
may be affected by the disease itself, independent of 
the amount of pigment present (see Section VI). 
D. PREOPERATIVE PRESSURE 
Several papers have reported that the greatest 
absolute pressure reduction occurred in those pa- 
tients with the highest initial pressures.4’42.65.‘9’ 
““‘,“‘.‘iq.‘7’, Although knowledge of this relationship 
may be helpful in predicting IOP response in some 
glaucoma patients, not all investigators accept this 
correlation.‘“’ Most investigators, however, do be- 
lieve that the relationship is linear and that the 
average pressure drop obtained in primary open 
angle glaucoma is usually 30% or less. Although not 
absolute, this figure can serve as a guide in predict- 
ing the maximal response that could be reasonabl) 
expected in a given patient.““,‘“” 
E. RESULTS IN THE FELLOW EYE 
Primary open-angle glaucoma is usually a bilater- 
al disease, although there may be some asymmetry 
between the two eyes as to the time of presentation 
and the severity of the disease. Exfoliation and pig- 
mentary glaucomas are bilateral in the majority of 
patients. Therefore, it is not unusual to have a pa- 
tient who has already had ALT in one eye and pre- 
sents with medically uncontrolled IOP in the sec- 
ond eye. Does the result in the first eye indicate 
what will happen in the second eye? In one of the 
early reports on ALT, the authors state that there 
was an asymmetric response between eyes in 9 of 19 
patients, but did not provide detailsfi’ Two later 
larger studies in which statistical analysis was per- 
formed found a significant correlation between the 
response in the two eyes. In one of these studies the 
correlation was still present three years after treat- 
ment,“.“‘~ 
These later studies are more in keeping with our 
own results. In general, if a good response has oc- 
curred in the first eye, the second eye will also do 
well. Conversely if we have not obtained much re- 
sponse in the first eye, it is uncommon for us to see a 
good response in the second eye. 
F. STAGE OF GLAUCOMA 
Some observers believe that ALl‘ is more success- 
ful in early glaucoma than in more advanced dis- 
ease. Wise states that 51% of eyes with a cup/disc 
ratio of 0.9 or more required surgery subsequent to 
ALT as compared to only 15% of eyes with smaller 
cup/disc ratios. 17” On the other hand he states that 
the prelaser average pressure and pressure drop 
from ALT were similar in the two groups. Thus, he 
is probably indicating that eyes with more advanced 
glaucomatous damage require a lower IOP to halt 
progression of disease, and not that ALT has a less- 
er IOP lowering effect in these eyes. Tuulonen et al 
studied factors influencing the outcome of laser tra- 
beculoplasty. They reported that severity of the 
glaucoma alone would have been a significant pre- 
dictor, but its importance was lost when the indica- 
tion for treatment was included.“‘“,“I‘hey also found 
that previous use of pilocarpine was a negative pre- 
dictive factor. 
VI. Diagnosis-related Effkacy 
of Treatment 
A. PRIMARY OPEN-ANGLE GLAUCOMA 
The response to argon laser trabeculoplasty 
(ALT) seen in POAG could be designated as the 
standard against which the success rates in other 
types of glaucoma can be compared. (See Section 
IV for explanation of success.) In large studies of 
POAG patients with average follow-up of five 
months or more, success rate of‘72.5% to 97% have 
been reported.:“,‘:‘,’ lH,I'%i 
In two of’ the larger reported series in the IJnited 
States, Thomas et al found an average IOP reduc- 
tion of 30.4%’ in 237 eyes, which is similar to the 
29.8% decrease in 222 eyes reported by Horns et 
al.“’ Both of these studies had fairly short follow-up 
periods, ranging from one week to two years. In 
Germany, Lund”’ reported IOP control in 94% of 
eyes with chronic simple glaucoma after one year, 
which dropped to 82% after two years. 
B. PIGMENTARY AND EXFOLIATION 
GLAUCOMAS 
As mentioned previously, some investigators 
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have correlated an increased success rate of ALT 
with the presence of trabecular pigmentation in 
open-angle glaucoma patients.g~4g,‘07*‘4” However, 
Lunde reported that ALT worsened pressure con- 
trol in five of 13 treated eyes with pigmentary glau- 
coma.68 This was particularly true in older patients 
with glaucoma of longer duration. Lieberman et al 
found that 7 of their 16 pigmentary glaucoma eyes 
(44%) had acceptable pressure reduction (an aver- 
age of 7.3 mm Hg) though failure was also more 
common in slightly older individuals.65 These re- 
sults may suggest that chronic trabecular damage 
from pigment can make the meshwork more resis- 
tant to the ameliorating effects of ALT. 
Contrary results were reported by Thomas et al, 
who obtained acceptable pressure levels in all of six 
pigmentary-type glaucomatous eyes treated with 
ALT.lz8 The average pressure drop in these eyes 
was 40%, a response second only to exfoliative glau- 
coma, which suggested that pigmentary glaucoma 
was a reasonable indication for ALT. Success of 
ALT in pigmentary glaucoma has also been de- 
scribed elsewhere.67’g7~‘“5 We have obtained good 
results in the majority of our pigmentary glaucoma 
patients and recommend ALT to those patients 
whose disease is not controlled medically. 
Thomas et al reported a 97% success rate in a 
small number of individuals with exfoliative glauco- 
ma. “’ Other authors have reported considerable 
success with ALT in these patientsg6 and some have 
related this to the increased degree of pigmentation 
typically found in this type of glaucoma.5 Of con- 
cern was the report from Higginbotham and Rich- 
ardson,“x which showed that, despite having a large 
immediate pressure response to ALT, these pa- 
tients failed at a faster rate after both initial and 
second-stage treatments, as compared to POAG 
controls. Pohjanpelto also reported late failures in 
this group of patients.H7 However, Sherwood and 
Svedbergh’“’ reported a 70% success rate in 55 eyes 
and late failure in only two patients. Because of the 
rather marked reduction in IOP that we have seen 
in our exfoliation syndrome patients, we have no 
hesitation about recommending ALT for our medi- 
cally uncontrolled patients. We do, however, warn 
the patients that any reduction in IOP may be tran- 
sient in nature. 
C. LOW TENSION GLAUCOMA 
A large study of patients with progressive low 
tension glaucoma (or, more correctly, normal ten- 
sion glaucoma) was reported by Sharpe and Sim- 
mons,‘20 who treated 85 eyes with this diagnosis. All 
subjects selected for inclusion into the study dem- 
onstrated progressive visual field loss or optic nerve 
damage despite maximal intraocular pressures of 
less than 19 mm Hg with medications. This group 
included classical low-tension eyes, but also includ- 
ed POAG eyes that progressed despite “acceptable” 
IOPs. Success was defined as a pressure drop of at 
least 20%, no need for increased medications, stable 
visual fields, and no subsequent glaucoma surgery 
(average follow-up, 30 months). Using these very 
rigid guidelines, treatment was found to be success- 
ful in 46.3% of the patients. Among “failures,” how- 
ever, visual field progression or requirement for 
surgery occurred in only 11 eyes, despite a pressure 
reduction of less than the desired 20%. Separation 
of patients into post ALT pressure groups of low 
(13-19 mm Hg), very low (lo-12 mm Hg), subnor- 
mal (6-9 mm Hg) and hypotony (O-5 mm Hg) re- 
vealed the best success in patients achieving the 
lowest pressures. The authors’ results support the 
widely held belief that reduction of pressures below 
the 12 mm Hg level can slow glaucomatous pro- 
gression. They recommended consideration of 
ALT in all low tension glaucomatous patients, espe- 
cially if surgical intervention is the only alternative. 
A sobering feature in this report was an early escape 
phenomenon, with many of the failures occurring 
by six months. 
Schwartz et al”’ looked at a similar goup and 
defined success as a pressure reduction of as little as 
2 mm Hg in addition to no further held progres- 
sion. They reported a much more optimistic success 
rate of 73%, but also reported a discouraging loss of 
effect with time. The average pressure drop of 5.8 
mm Hg at two months fell to 4.9 mm Hg at one year 
and 2.0 mm Hg at two years.“’ In another study, 
Watson et al found that ALT was unsuccessful in 
further reducing IOP in patients whose initial pres- 
sures were 21 mm Hg or less.‘“’ 
D. APHAKIA/PSEUDOPHAKIA 
ALT in aphakic glaucomatous eyes would seem 
an ideal treatment in light of the reported low hlter- 
ing success rates and higher incidence of complica- 
tions in these cases.44 It is important to note that 
much of the literature deals with ALT following 
intracapsular cataract extraction (ICCE), a tech- 
nique that has been replaced by extracapsular cata- 
ract extraction (ECCE). Success rates have varied 
from 64.7% of 22 eyes (Horns)‘” and 71.4% of seven 
eyes (Goldberg)“’ to 47% of 15 eyes (Spaeth).lZx 
Other reports have conflicted as to the degree of 
pressure response obtained in aphakia,““,“’ which 
further complicates the issue. Horns et al, for exam- 
ple, achieved an average pressure drop of 27.5%, 
which is markedly better than the 12.5% found by 
Thomas et al.“‘” We have found that the presence of 
vitreous in the anterior chamber of patients ad- 
versely affects the outcome ofALT. Although exten- 
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sive experience with ALT following ECCE and im- 
plantation of a posterior chamber intraocular lens is 
as yet unpublished, we believe, as does Thomas,“‘” 
that a desirable pressure reduction can be obtained 
in many of these eyes. Act.ual success rates and mag- 
nitude of pressure reduction await further data. It 
would seem reasonable to attempt ALT in aphakic 
patients who are otherwise good candidates; how- 
ever, results are unpredictable and the need for 
possible conventional surgery should be under- 
stood. 
A related question concerns whether to perform 
ALT before cataract extraction in those glaucoma 
patients who have significant lens opacities. In a 
comparison between combined filtration surgery 
(with and without anterior chamber lens implanta- 
tion) and ALT prior to the cataract extraction, the 
combined cataract extraction and filtering surgery 
appeared more successful in obtaining adequate 
pressure reductions.“” Nonetheless, completion of 
full-circumference ALT in the months before ECCE 
is an option found useful by some clinicians. Brown 
et al, for example, reported that cataract extraction 
with or without posterior chamber lens implanta- 
tion did not result in any loss of pressure control 
obtained by previous argon laser trabeculoplasty.” 
Cataract surgery was performed 2-26 weeks after 
the completed ALT (one or two sessions of 100 
spotsi360”) in 28 eyes. The average pressure de- 
crease of 8 mm Hg was maintained following sur- 
gery, and this is certainly much more acceptable 
than the 2.1 mm Hg pressure reduction reported 
by ‘l’homas et al, who performed ALT after 
ICCE.““’ In summary, although combined trabecu- 
lectomy/cataract procedures are useful in some in- 
dividuals, full-circumference ALT in one or two ses- 
sions prior to cataract surgery does seem 
reasonable in selected cases. 
E. UVEITIS 
The success rate of ALT in uveitic open angle 
eyes has ranged from 0% to 75% in different stud- 
‘~i.:~X.,i‘~.fi.~.!l7.1L’X ies: Results must be cautiously inter- 
preted, since these eyes consist of a very heteroge- 
neous population in terms of etiology and degree of 
angle damage. Treatment is directed toward those 
aspects of the angle that remain open and accessi- 
ble. Because ALT has been known to cause iritis in 
some patients (Section V), it would seem prudent to 
approach laser treatment very cautiously on an in- 
dividual basis, employing careful follow-up and 
care. 
Although ALT cannot be performed in angles 
with complete synechial closure, peripheral irido- 
plasty may open the angle sufficiently to allow for 
some treatment, but, again, the iridoplasty may 
cause exacerbation of the uveitis. 
F. ANGLE RECESSION 
Results of treatment in eyes with traumatic angle 
recession have been mixed, with success rates re- 
ported to be 0% to 63% in small numbers of pa- 
tients.JO.“i.li~.l~~,l:~~ As in uveitis, the lack of uniformity 
in severity of damage and the presence of other 
associated ocular pathology make interpretation of 
these numbers difficult. Some of our patients have 
benefited from treatment, although we cannot pre- 
dict who will be most likely to do so, and we have 
experienced severe post-laser IOP elevations up to 
70 mm Hg. More data are required before precise 
recommendations can be made, but, in general, we 
recommend extreme caution. 
G. COMBINED MECHANISM 
Hitchings described marked pressure reduction 
in 16 such eyes utilizing a two-stage procedure of 
peripheral iridotomy followed by ALT one to 12 
weeks later.‘“’ When iridotomy does not suffice, 
some clinicians utilize an initial peripheral irido- 
plasty to obtain better visualization of the mesh- 
work.“” 
H. STEROID-INDUCED GLAUCOMA 
ALT in steroid-induced glaucoma has been at- 
tempted with varying success. Thomas et al first 
reported minimal post-laser response in two pa- 
tients who underwent ALT to control unsatisfactory 
pressures associated with steroid use.‘“” A more re- 
cent study involving a larger group of patients re- 
ported an average decrease in pressure of35%1 in 12 
individuals who were receiving oral prednisone. 
Unfortunately, the amount of follow-up time is not 
mentioned in this article. Although more data will 
help to settle the controversy, the use ofALT in this 
group of patients prior to conventional surgery 
seems reasonable. 
I. JUVENILE GLAUCOMA 
At present there is no consensus as to the precise 
definition of ‘juvenile glaucoma.” Altholugh it could 
be defined as the development of glaucomatous fea- 
tures before the age of 40, specific angle findings, 
such as a high insertion of the iris, have been de- 
scribed and may help identify this as a unique enti- 
ty.““’ Horns et al reported that only 4 of their 10 
‘tjuvenile-type” patients were able to avoid conven- 
tional surgery after ALT.“” In addition, a low suc- 
cess rate in younger individuals as a group has been 
reported by Safran et al.‘“” Of particular concern, 
however, was Wilensky and Weinreb’s report of fail- 
ure in six patients following ALT, four of whom 
were made worse and required filtration surgery.“” 
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J. PREVIOUS EYE SURGERY 
As previously mentioned, ALT has been per- 
formed in eyes that had undergone prior intraocu- 
lar surgery. On the basis of their experience with a 
small number of eyes, Lieberman et a1,65 as well as 
Forbes and Bansal”‘.“’ reported that eyes that had 
only one previous intraocular procedure had an 
ALT response similar to that obtained in eyes that 
had no previous surgery. 
ALT has been found to be useful in some patients 
who have had unsuccessful filtering surgery. Fell- 
man and associates,28 for example, reported a 67% 
success rate of ALT in 30 previously filtered eyes 
that did not have satisfactory control of IOP. (Fail- 
ure following ALT was defined as sustained unac- 
ceptable pressure levels, visual field progression 
and/or the need for further filtering surgery). Simi- 
larly, Robin and Pollack were able to avoid addi- 
tional filtration surgery in six of seven previously 
filtered eyes that were treated with ALT.” In an 
unrelated report, a 71% success rate was attained in 
34 previously filtered eyes.“’ In summary, the use of 
ALT would seem to be a reasonable therapeutic 
option in previously filtered eyes, especially when 
one considers the lower success rate encountered in 
repeated filtration surgery. 
Finally, ALT has recently been described to be of 
benefit in post-keratoplasty patients by Van Meter 
et a1.15’ They found a satisfactory response in small 
groups of aphakic and phakic post-cornea1 trans- 
plant patients during a mean follow-up period of 12 
to 37 months. 
K. MISCELLANEOUS 
ALT has been performed in a wide variety of 
other glaucomas, such as congenital glaucoma, iri- 
docorneal endothelial syndrome, and Sturge-Web- 
er; however, not enough subjects with follow-up are 
available to determine whether ALT is a viable al- 
ternative in these and other secondary glauco- 
mas 65,97,12X 
VII. Complications 
As with all therapeutic interventions, benefits 
must be weighed against potential risks. ALT has 
been associated with several adverse effects, rang- 
ing from minor to catastrophic (Table 1). Together, 
physician and patient must be aware of these possi- 
ble complications before proceeding with laser 
therapy. 
A. PRESSURE ELEVATION 
Elevation of IOP following treatment has been 
reported by most investigators. Thomas et al re- 
ported a 25.3% incidence of pressure elevation in 
300 treated eyes. This occurred in 20.9% of eyes 
TABLE 1 
Complications Associated with ALT 
Intraocular pressure rises (transient and chronjc) 
Loss of vision (central island) 
Peripheral anterior synechiae 
Uveitis 
Hyphema 
Cornea1 abrasion/punctate keratopathy 
Cornea1 burns (epithelial/endothelial) 
Syncope 
Adverse effect on future filtering success 
considered successful, as compared to 47% of eyes 
that were later “failures.“‘36 In another study, 
Horns et al reported a 9.2% incidence of IOP eleva- 
tion within the first 28 days after treatment.5” When 
considering IOP elevation that occurred at any time 
following treatment (19.5% of patients), 11% of 
these eyes had between 1 and 4 mm Hg of elevation, 
6.3% had a rise of 5-9 mm Hg, and 2.1% had a rise 
of greater than 8 mm Hg. Krupin et al reported a 
much higher (53%) incidence of pressure elevation, 
with a range of l-22 mm Hg in 57 eyes.6” Forbes 
and Bansal”’ found a 2 1% overall incidence of pres- 
sure elevation, with a range of 7-27 mm Hg. In 
agreement with the earlier report of Thomas et al, 
Forbes and Bansal noted a failure rate of 36%, twice 
that of the entire treated group, in those patients 
who experienced pressure elevation. Hoskins and 
coworkers reported a 22.5% incidence of IOP eleva- 
tion within the first six hours following treatment.54 
Others have reported similar results.‘75 
The Glaucoma Laser Trial Research Group”’ re- 
cently reported its findings regarding the acute ef- 
fects of ALT on IOP in 27 1 eyes assigned to receive 
ALT as a first intervention (two sessions; four weeks 
apart). The incidence of an IOP rise 5 mm Hg or 
greater above baseline was noted in 34% of patients 
after one or both treatment sessions. Twelve per- 
cent of eyes demonstrated an increase of 10 mm Hg 
or more. Patients who had pressure elevation after 
the initial 180” treatment were more likely to dem- 
onstrate a rise in pressure after treatment two. Pig- 
mentation of the trabecular meshwork proved to be 
the most significant risk factor for this acute pres- 
sure rise. In a separate study Keightley et al, using 
two-minute tonography performed with a pneumo- 
tonography unit, reported a correlation between a 
low coefftcient of outflow and a greater risk of a post 
treatment rise in IOP.“5” No statistical analysis was 
provided, however. 
In terms of the onset of the elevation, Weinreb et 
al found that post-laser pressure elevation was most 
likely to occur within three to five hours in the 360 
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treatment group and earlier in the 180” treatment 
group.‘“’ Krupin et al treated 360” of angle and 
found that 8 of 10 eyes that experienced a pressure 
elevation did so within the first post-treatment 
hour.“” The remaining two eyes demonstrated 
pressure elevation at four hours and at seven hours, 
respectively. These results led the authors to rec- 
ommend careful follow-up of patients, especially in 
the immediate postoperative period. 
Over the long-term, Thomas et al reported that 
ALT made the pressure status worse in 3% of all 
eyes (primary and secondary glaucomas).‘“” Simi- 
larly, Horns et al found that 7.4% of patients had a 
higher final post-treatment pressure reading”” and 
Hoskins and coworkers reported this in 6% of their 
patients.“’ These reports indicate that ALT can 
sometimes permanently worsen the pressure status 
in some patients. This risk must be appreciated by 
the physician and understood by the laser candi- 
date. 
Since, in some cases, an acute rise in IOP follow- 
ing ALT has been associated with loss of central 
vision, I :(6.154 avoidance of post-laser pressure eleva- 
tion has been a goal of laser therapists. Variations in 
laser burn location, number, power, and duration 
have all been tried to minimize this untoward re- 
sult. Schwartz et al reported less IOP elevation with 
anterior placement of the laser burns.“” Thomas et 
al also have correlated placement of the burns to 
pressure elevation.‘:‘7 They noted a higher inci- 
dence of pressure elevation in reports from investi- 
gators who treated the posterior meshwork (Ki- 
tazawa et al, International Symposium on Laser Surgery 
for Glaucoma, Saratoga Springs, NY, July 20-21, 
198 1) as compared to those who treated the anteri- 
or trabecular band (Beckman H, International Syvn- 
posiuvn on Laser Surger?, for Glaucovna, Saratoga 
Springs, NY, July 20-21, 1981). Kitazawa and co- 
workers in a separate report, however, did not find 
any difference in those patients treated on the pos- 
terior versus the anterior aspects of the trabecular 
meshwork.“x 
Many investigators have reported significantly 
fewer and lower pressure elevations (frequency, 
magnitude, or duration) when they treated only 
180” per session as opposed to the full circumfer- 
ence of the angle. Ll”,,~~.~N,1’1:1.‘:16.‘~ti Weinreb et al, for 
example, randomized 40 patients with different 
types of glaucoma into groups of either 180” or 360” 
treatment.“‘” They corrected pressure changes for 
diurnal variation by subtracting the pressure 
change in the untreated eye from that in the treated 
eye. They found that this mean corrected maximal 
pressure rise following trabeculoplasty was 1.3 * 
4.91 mm Hg in the 180” group, as compared to 7.35 
+- 9.28 mm Hg in the 360” group. This difference 
was significant, and was found to be of even greater 
magnitude when eyes not experiencing pressure 
spikes were excluded. 
Another proposed association of post-ALT IOP 
elevation is laser energy. In monkeys, Quigley and 
Hohman demonstrated an increased risk of pres- 
sure elevation when higher levels of laser energy 
were delivered to the primate trabecular mesh- 
work.“’ On the basis of this work in animals, these 
investigators proposed not exceeding 0.1 set dura- 
tion to maintain a window of safety against inadver- 
tent over-treatment, damage to the angle struc- 
tures, and subsequent pressure elevation in clinical 
human studies. Investigators have, in fact, de- 
scribed more frequent postoperative pressure in- 
creases with higher laser energy levels.““,‘“” For 
these reasons, clinicians generally limit treatment to 
power levels of 500 to 1000 mW. 
The etiology of post-treatment pressure elevation 
has proved elusive. In light of the known effects of 
prostaglandins on IOP, these substances have been 
suspected to be possible causative factors in the 
post-ALT pressure spikes. Neither aqueous analy- 
sis”” nor treatment with antiprostaglandin agents 
have corroborated a role for prostaglandins in 
acute post-laser pressure rise.L”1.5’r.H”.‘~~,‘,~~ Greenidge 
and associates examined histological specimens 
from four patients with medically unresponsive 
pressure elevation following ALT with and without 
peripheral iridotomy.‘“” These specimens revealed 
intertrabecular inflammatory debris not seen in 
eyes without pressure elevation, which suggested 
an inflammatory etiology. Koss and coworkers re- 
ported similar findings in cynomolgus monkeys.“” 
Unfortunately, pretreatment with topical steroids 
for 36 hours before laser therapy has not been 
shown to prevent postoperative pressure rises or to 
affect final pressure outcomes.“” Ofner et al report- 
ed that instillation of 4% pilocarpine in the immedi- 
ate post-laser period reduced the frequency and 
magnitude of pressure elevations compared to con- 
trols.“” They postulated that post-laser pressure 
spikes might be due to a mechanical blockage of 
outflow channels that could be somewhat alleviated 
by a cyclotonic agent, such as pilocarpine hydro- 
chloride. 
Various attempts have been made to control 
postoperative pressure spikes with pharmacologic 
agents and other means. Indomethacin, flurbipro- 
fen, and corticosteroids, as mentioned previously, 
were not efficacious in preventing this complica- 
tio*~.“.l”x.l~~.l.~~ 
Recently, Robin and associates have reported on 
their experience with the use of apraclonidine hy- 
drochloride, a member of a relatively new class of 
agents, the alpha-2 agonists.““’ In a prospective ran- 
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domized, double-masked study, these investigators 
compared 1% apraclonidine hydrochloride against 
placebo in 73 eyes undergoing 360” ofALT. No eyes 
in the apraclonidine hydrochloride group, com- 
pared to 18% of the placebo group, had pressure 
elevations of 10 mm Hg or greater. Only 2 1% of the 
treated group compared to 59% of the placebo 
group, had any elevation at all. These findings were 
confirmed by Brown et al.” Because it is a topical 
drug, apraclonidine hydrochloride should circum- 
vent the side effects associated with osmotics or car- 
bonic anhydrase inhibitor type agents that are often 
used to treat post-laser pressure elevation. In addi- 
tion, since apraclonidine hydrochloride is not pres- 
ently used in the longterm treatment of glaucoma, 
this agent could have the distinct advantage of pre- 
venting pressure spikes when used in patients re- 
ceiving maximal medical therapy. 
B. LOSS OF CENTRAL ISLAND OF VISION 
It should come as no surprise that even transient 
elevation in intraocular pressure has been associat- 
ed with permanent visual loss. Laser trabecular 
treatment in animals that caused pressure elevation 
has resulted in subsequent optic nerve damage.“zg’ 
Clinical reports from Thomas et alIs and Weinreb 
et ali5” describe patients with end-stage disease who 
lost remaining central islands of vision following a 
post-laser pressure rise. Although a cause-effect re- 
lationship was assumed, progressive loss of vision 
has also occurred in patients having had no appar- 
ent pressure elevation after ALT.So In counseling 
patients and weighing options, clinicians should re- 
member that this catastrophic complication is not 
limited to ALT, considering that it has been report- 
ed following conventional filtration surgery.15’ 
C. PERIPHERAL ANTERIOR SYNECHIAE 
Schwartz et al”” and Wilensky and Jampol’“” 
were among the first investigators to report periph- 
eral anterior synechiae (PAS) formation following 
ALT. In their group of 35 eyes, Schwartz et al noted 
PAS in 29% of their patients. They were not able to 
correlate PAS occurrence to success or failure of the 
treatment and did not find any relationship to racial 
characteristics. Wilensky and Jampol reported PAS 
in two patients who had developed a significant 
postoperative uveitic reaction. Other studies have 
reported rates of PAS formation ranging from 12% 
to 47% following similar treatment protocols.‘“6,‘4’ 
Unlike Schwartz et al, Pappas and associates”” found 
a much higher incidence of PAS in black patients 
(91%) compared to whites (13%). They also report- 
ed that treatment with topical indomethacin did not 
prevent this complication. The Glaucoma Laser 
Trial Research Group3’j reported an incidence of 
Fig. 5. Typical pattern of peripheral anterior synechiae 
(PAS) produced by ALT. (Reprinted from Schwartz AL et 
al”’ with permission of the authors and publisher of Oph- 
thalmology.) 
PAS formation in 46% of those eyes that received 
ALT as an initial intervention. In 33% of the eyes 
peripheral anterior synechiae involved the trabecu- 
lar meshwork. Factors presumed to predispose to 
PAS formation include high power levels and poste- 
rior placement of the burns. Traverso et al reported 
that ALT was no less effective when burns were 
placed anteriorly, but that PAS developed in only 
12% of anteriorly treated eyes, compared to 43% of 
those eyes treated posteriorly.‘4’ Rouhiainen and 
associates reported a similar relationship, and ob- 
served more PAS formation in those eyes receiving 
higher levels of laser power.‘06 
Many investigators have suggested that PAS, 
which usually just extend to the scleral spur, are of 
no real clinical significance (Fig. 5).“‘j~“~*‘“~ In con- 
tradistinction, Rouhiainen et al reported that those 
eyes with PAS demonstrated smaller post-laser de- 
creases in intraocular pressure.‘06 Treatment of the 
anterior aspects of the trabecular meshwork is rec- 
ommended to minimize PAS formation. 
D. UVEITIS 
Uveitis after ALT has generally been transient 
and of minor significance.“’ Wilensky and Jampol, 
however, described two patients who developed se- 
vere nongranulomatous iritis following ALT. In 
one patient, this condition lasted nine months and 
appeared recalcitrant to topical, sub-Tenons, and 
systemic corticosteroids.‘“” Pappas and colleagues 
found that those eyes in which “significant” iritis 
developed were more prone to PAS formation8” 
Most clinicians now use frequent topical steroids in 
the immediate post-operative period, which is 
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thought to help minimize this undesirable compli- 
cation.;~.‘:~” 
E. HYPHEMA 
Transient microhyphemae were found in 2.3% of 
treated patients in the study by Thomas et al.“” 
Earlier, Wise had reported a similar incidence of 
57~.‘~‘” These small hyphemae can usually be con- 
trolled by direct photocoagulation, as described by 
Wise”‘“,‘“” and Thomas et a1,1s4 and are of minor 
significance. 
F. CORNEAL SEQUELAE 
Cornea1 burns of both the epithelium and deeper 
layers have been seen and described by several au- 
thors, but these were in the early studies and have 
not been reported recently.x”,‘““.“‘” Hong et al re- 
ported significant increases in cell size following la- 
ser trabeculoplasty in 10 eyes at 6 and 12 months of 
follow-up.“” In other prospective studies, however, 
no real effect on endothelial morphology, cell den- 
sity, “““’ or functionlg could be found. Although 
transient worsening of cornea1 edema in a patient 
with Fuchs’ dystrophy Ifi” and late-onset bullous ker- 
atopathy in a traumatized eye’“” have been report- 
ed, we do not believe that permanent or significant 
cornea1 damage is a likely complication. Perhaps 
more significant is that cornea1 pathology may ad- 
versely affect the view of the angle structures, mak- 
ing treatment more difficult and at times impossi- 
ble. 
G. SYNCOPE 
As with any procedure that involves pressure on 
the globe or ocular manipulation in anxious pa- 
tients, syncope should be anticipated. Hoskins et al 
reported four such patients, three of whom were 
less than 40 years old.;‘” It is unclear whether the 
laser aspects of the procedure might actually play a 
role in this adverse reaction. 
H. EFFECT ON FUTURE FILTRATION 
SURGERY 
In recent years, there have been thoughts ex- 
pressed in the literature that ALT may lessen the 
chances of success of conventional filtration sur- 
gery,GVl.!‘.’ In a series of 438 trabeculectomies on 
435 eyes of 344 patients, Gross et al reported an 
overall 281(’ incidence of encapsulated blebs, in- 
creasing from 26% in 1983 to 33% in 1986. Patients 
with previous ALT demonstrated a doubling in the 
incidence of encapsulated blebs compared to those 
without it (33%’ versus 16%).“” Perkins et alx” and 
Richter et al!“’ have also expressed the concern that 
AL’l‘ may in some way be related to the increased 
rate of encapsulated blebs seen in recent years. In 
the study by Richter and associates, encapsulation 
of the bleb was found to have occurred in 56 of 409 
consecutive filtering procedures during a 40- 
month period. This complication occurred in 42 of 
272 (15.4%) eyes that had received previous ALT 
compared to only 4 of 85 non-laser-treated eyes 
(4.7%). Neither the interval between laser and fil- 
tration surgery nor the number of spots were statis- 
tically linked to the risk of encapsulation in these 
subjects. The Advanced Glaucoma Intervention 
Study, which will be described in Section IX, may 
provide definitive information regarding this asso- 
ciation. Until that time, however, we would discour- 
age the routine use of ALT in every presurgical 
patient unless a reasonable chance of success exists. 
It is worthwhile noting, however, that ALT avoids 
much of the acute morbidity usually associated with 
conventional filtration procedures. Post-treatment 
discomfort, medical care, and requirements for fol- 
low-up are usually less of a problem with this tech- 
nique. Risks of expulsive choroidal detachments, 
endophthalmitis, and anesthetic reactions are 
avoided. ALT also has the distinct advantage of 
avoiding progressive cataract formation, which is 
often seen in the years following conventional filtra- 
tion surgery.“’ 
VIII. Retreatment 
Unfortunately, most clinicians have seen a return 
to unacceptable intraocular pressure levels in some 
of their patients who initially had been controlled 
following ALT. Since filtration surgery is usually 
the next option, several investigators have been mo- 
tivated to try retreatment with AL?’ in selected 
cases. Starita et al retreated 17 eyes that had been 
classified as failures after initial full ALT.““’ In 35% 
of eyes, a reduction in IOP of greater than 3 mm Hg 
along with stabilization of visual fields was obtained 
(average follow-up, 12 weeks). Three of the patients 
(18%) experienced an acute rise in IOP 2 10 mm 
Hg within four hours of treatment and one addi- 
tional patient had a similar elevation at one week. 
Brown and associates retreated 26 eyes with both 
primary and secondary glaucomas that had shown 
pressure reduction following previous initial ALT 
treatment (360” in one session or 180’ in two ses- 
sions), on average, 16 months earlier.” Following 
the retreatment, which was divided into two ses- 
sions of 180” in most subjects, ten eyes (38.5%) had 
pressure elevation averaging 9.9 mm Hg and three 
of these had increased pressure ranging from 10 to 
37 mm Hg. Eight of these retreatment failures dem- 
onstrated progressive visual field deterioration and 
required surgery within one month. Fourteen eyes 
(54%) did respond with a pressure reduction aver- 
aging IO.4 mm Hg. These eyes had stable visual 
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fields and were considered retreatment successes at 
an average follow-up of five months. 
Richter and coworkers retreated 180” of angle in 
40 eyes that had undergone previously successful 
ALT with 360” of treatmentgY Retreatment success, 
described as an IOP decrease of 3 mm Hg or more, 
stable optic disc and visual fields, and avoidance of 
conventional surgery was achieved in only 32% of 
all eyes. Furthermore, Kaplan-Meier survival anal- 
ysis predicted a progressively lower likelihood of 
maintained success, particularly after one year. Un- 
like in the study by Brown et al,” who treated the 
full circumference, no patients experienced IOP 
elevation greater than 6 mm Hg in the immediate 
post-laser period and none required urgent filtra- 
tion surgery as a result of the technique. 
Recently, Grayson et al reported on their experi- 
ence with retreatment of 38 eyes, most of which 
were phakic and had POAG.“’ Retreatment was 
performed an average of two years following the 
initial treatment, which was at first successful. They 
reported a successful outcome in 73% of eyes at 12 
months following retreatment. However, of those 
15 eyes that underwent a second retreatment at 6 to 
47 months after the first retreatment, eight (53%) 
required conventional filtration surgery. It is im- 
portant to recognize that the initial ALT treatment 
consisted of fewer burns (mean = 65) than are usu- 
ally applied by most clinicians. Similarly, Weber et 
al retreated 37 eyes classified as late treatment fail- 
ure with an additional 50 laser spots scattered over 
360”.15” The IOP decreased by an average 6.4 mm 
Hg one month after the retreatment and all eyes 
were considered to have had a successful response 
at one month. The success rate had dropped to 70% 
by one year, and to 47% at 16 months. In a smaller 
series, Messner et al found retreatment successful in 
only a small percentage of their patients. They have 
raised the point that ALT retreatment may serve to 
delay necessary filtering surgery in the majority of 
cases.76 
As can be seen, experience with retreatment has 
been variable and only a minority of patients have 
been able to avoid progression of disease for more 
than an additional year or two. AI1 patients should 
be aware of the lower success rate, and the possibil- 
ity of acute and chronic pressure elevation that have 
been described with retreatment. We tend to limit 
the use of retreatment to very elderly or infirm pa- 
tients who experienced a good response to ALT that 
had been performed at least several years earlier. 
IX. Ongoing Studies 
A. ALT AS A PRIMARY TREATMENT 
The use of ALT as a primary treatment has been 
described by several authors. In countries where 
access to medication and follow-up are limited, ALT 
appears to offer many advantages. Thomas et al 
reported their experience with 30 eyes of 20 Egyp- 
tian patients primarily treated with ALT for open 
angle glaucoma (average follow-up, 7% months).‘“” 
Success, which was defined as a pressure of less than 
22 mm Hg without further optic disc or visual field 
progression, was achieved in 83% of subjects. In a 
similar study, but in an English population, Ro- 
senthal et al reported that only 55% of patients ob- 
tained an IOP less than 22 mm Hg.‘OJ 
In a retrospective study, patients who either were 
reluctant to use medical therapy or had other prob- 
lems that precluded good medical compliance. 
Tuulonen reported an 81% success rate at 12 
months (59 eyes) and 78% success (46 eyes) at 18 
months after using ALT as the primary treat- 
ment.‘44 In a prospective follow-up of 32 eyes that 
received ALT as their initial treatment, 50% had 
pressures less than 22 mm Hg at five years.‘“’ Tuu- 
lonen is now conducting a prospective randomized 
study comparing ALT and medical treatment. At 
the end of one year there was no statistically signili- 
cant difference between the two groups.‘46 
A second prospective study of ALT as initial ther- 
apy for open-angle glaucoma is being conducted in 
London. In this study, 168 patients with open-angle 
glaucoma were randomized into three groups. The 
first group was treated with trabeculectomy, the 
second with laser trabeculoplasty, and the third 
with medication. Interim analysis showed lowest 
mean IOP and least diurnal variation in the trabec- 
ulectomy group. Medical therapy was least effective 
in lowering IOP.7” 
A third multicenter prospective trial study is the 
Glaucoma Laser Trabeculoplasty Trial (GLT) spon- 
sored by the National Eye Institute in the United 
States. Twenty-seven patients who have primary 
open-angle glaucoma are being evaluated over a 
minimum five-year time period. One eye was ran- 
domly selected to begin treatment with laser trabec- 
uloplasty while the other eye is treated with medica- 
tion. Medication was added to either eye as needed 
to obtain adequate IOP control and prevention of 
further visual field loss. 
The two year follow-up results of the GLT Study 
have recently been published. In the eyes that were 
treated with ALT as the initial treatment, 44% re- 
mained under control after two years of follow-up 
with the laser treatment alone, and 70% remained 
under control with either the laser alone or a com- 
bination of the laser treatment and timolol. If an- 
other single topical antiglaucoma drop (pilocarpine 
or dipivefrin) was substituted for the timolol, then a 
total of 84% of eyes were controlled by laser alone or 
laser plus one antiglaucoma medication. Of eyes 
begun on medical treatment, 30% had the intraocu- 
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lar pressure controlled at the end of two years with 
timolol alone. If another single antiglaucoma topi- 
cal medication (again, pilocarpine or dipivefrin) 
was substituted for the timolol, then an additional 
2 1%~ were controlled, and, thus, a total of 5 1% of the 
medically treated eyes were controlled by a single 
agent. With any combination of one or two anti- 
glaucoma drops, a total of 66% of eyes were under 
control at the end of two years. 
Looking at the same data in the opposite way, 
16%’ of the eyes were not controlled at the end of 
two years by laser alone or a combination of laser 
and one antiglaucoma medication, while 34% of the 
medically treated eyes were not controlled by one 
or an)’ combination of two antiglaucoma medica- 
tions at the end of two years. Also, the average intra- 
ocular pressure in the eyes that were treated first 
with ALT was approximately 2 mm Hg lower than 
the average intraocular pressure in the eyes that are 
treated with medicines alone. There was no signifi- 
cant difference at the end of two years in the visual 
field between the eyes treated first with the laser 01 
with medication. 
Among the arguments for beginning with laser 
treatment are that patients will be spared the expo- 
sure to the potential of serious side effects and com- 
plications of medical therapy and that patient com- 
pliance is eliminated as a factor in control of tht 
glaucoma. Since more than half the patients in the 
GLT Studys56ended up on medical therapy by the 
end of two years of follow-up, then those potential 
advantages were of only transient benefit to those 
patients. On the other hand, there clearly may be a 
convenience factor for the patient to use only one 
drug rather than the two, and the average IOP in 
the eyes treated with the laser was lower than that of 
the eves treated with medicine alone. Therefore, a 
reascinable case can be made to justify using ALT as 
the first avenue of treatment of primary open angle 
glaucoma. Whether these advantages are sufficient 
to justify this break with traditional practice and 
whether just two years of follow-up is adequate to 
make such a decision is something that each practi- 
tioner will have to decide individually. 
to 10% of the trabeculectomy group. 
A similar but much larger prospective study is the 
multicenter National Eye Institute sponsored Ad- 
vanced Glaucoma Intervention Study (AGIS). Indi- 
viduals will be randomized into one of two treat- 
ment pathways: 1) ALT followed by trabeculectomy 
if necessary, followed by repeated trabeculectomy 
as needed; or 2) trabeculectomy followed by AL?‘, if 
needed, followed by repeated trabeculectomy as 
needed. It is hoped that this study will not only 
provide indications for the use of ALT versus filter- 
ing surgery, but will also indicate whether ALT it- 
self has any effect on the success of subsequent fil- 
tering surgery. 
X. Recommendations for Treatment 
A. TREATMENT PARAMETERS 
Since many patients achieve a significant (and 
sometimes minimal) IOP reduction with treatment 
of only 1X0”, which reduces the risk of post-treat- 
ment elevated IOP, we recommend performing la- 
ser trabeculoplasty in two sessions. In rare instances 
when there is very advanced glaucomatous dam- 
age, we may deliver the treatment in 90” incre- 
ments. Usually the second treatment will be per- 
formed one month after the initial one, but 
occasionally when the IOP reduction has exceeded 
our treatment objective, we may defer the second 
treatment session. 
We recommend placing the treatment burns at 
the junction of the anterior border of the pigment- 
ed and nonpigmented trabecular meshwork. This 
seems to result in less pain during treatment, fewer 
peripheral anterior synechiae. and less postoper- 
ative inflammation. We use a 50~ spot fix 0.1 sec- 
onds. We differ among ourselves as to laser power. 
One of us uses a standard power setting (XOOmW) 
for all treatments while the other two vary the pow- 
er between 500 and 1000mW. depending on the 
tissue reaction. We all use blue-green argon lasel 
energy for the treatment. 
B. PATIENT MANAGEMENT AT THE TIME OF 
TREATMENT 
B. ALT VERSUS FILTERING SURGERY 
Patients are instructed to continue their usual 
glaucoma medication. In eyes with very advanced 
In 1984. Watson et al prospectively randomized 
medically uncontrolled glaucomatous eyes into sur- 
gical and laser treatment groups.“’ Although dif- 
ferences between the results prevented more de- 
tailed conclusions, the following statements were 
made by participating clinical centers: 1) ALT 
caused less of a pressure reduction than surgical 
trabeculectomy; and 2) 21% of patients in the ALT 
group required changes in their medical regimen 
or surgical intervention because of unsatisfactory 
pressures or progressive visual field loss as opposed 
visual field loss and for cupping of the optic nerve- 
head, a drop of apraclonidine is instilled in the eye 
at the conclusion of the laser treatment. The pa- 
tient’s IOP is then monitored hourly for three 
hours. If a significant elevation of 1OiP is detected 
(generally defined as a rise of 10 mm Hg), apraclo- 
nidine, a carbonic anhydrase inhibitor and/or hy- 
perosmotic agent, is administered. 
When the patient is allowed to leave, he is in- 
structed to begin using a topical corticosteroid drop 
in the eye everv two hours until bedtime that da> 
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and then four times a day for the next four days. 
The patient returns for a check-up in one week. 
C. CASE SELECTION 
We believe that ALT should be considered in 
most patients with primary open-angle glaucoma, 
exfoliation syndrome glaucoma, pigmentary glau- 
coma, and angle-closure glaucoma successfully 
treated with laser iridectomy but having residual 
elevated IOP. We frequently recommend it in low 
tension glaucoma and aphakic/pseudophakic glau- 
coma, but are much more selective about its use in 
eyes with uveitis, angle recession glaucoma and ju- 
venile glaucoma. Other factors besides the glauco- 
ma diagnosis must be taken into consideration in 
making the decision. What level of IOP is desired? 
In a patient with early POAG and IOP of 26 mm 
Hg, ALt may be appropriate since a 25% reduction 
will lower the IOP below 20 mm Hg. In a similar 
patient whose disease is advanced and the goal is to 
lower the IOP to below 15 mm Hg, filtration sur- 
gery may be more appropriate. 
IOP is still uncertain, a measurable increase in tono- 
graphic outflow facility has been demonstrated and, 
as such, ALT is one of the few therapeutic modali- 
ties that actually reverses a pathologic factor found 
in most open angle glaucomas. Reported success 
rates and degree of pressure reduction vary with 
the exact type of glaucoma, particular features of 
the patient population, and technique employed. 
The duration of effect is variable and, although it 
usually is thought to diminish with time, it does 
avoid the need for filtration surgery in many pa- 
tients. Studies are underway that should help to 
better determine the appropriate place for ALT in 
the treatment of the open angle glaucomas. 
Acknowledgments 
The authors wish to thank Ms. Laura Perez and Ms. 
Glenda Leachman for secretarial assistance and Ms. 
Kathy Louden for editorial assistance. 
References 
1. 
Another factor that must be considered is the age 
of the patient. As has been pointed out, younger 
patients do not tend to respond as well to ALT. Also, 
because of their longer life expectancy, younger pa- 
tients need their IOP reduction to be sustained for a 
longer time. As has been demonstrated, the ALT- 
induced IOP reduction does not appear to be per- 
manent in most cases. Therefore, in general, the 
younger the patient, the less likely we are to recom- 
mend ALT. Conversely, the older and more infirm 






C. TIME OF TREATMENT 7. 
The place of ALT in glaucoma therapy is in flux. 
Initially, we used it only in eyes uncontrolled on 
maximum medical therapy. With time we have 
gradually used it earlier in the therapeutic regimen. 
We now often use it prior to carbonic anhydrase 
inhibitors, as a substitute for miotics in symptomatic 
patients or prior to cataract extraction in otherwise 
controlled eyes. With the growing reports of the 
successful use of ALT as an initial treatment for 
glaucoma, it is possible that before long we may 






In a relatively short time, ALT has become a stan- 
dard in the treatment of various open angle glauco- 
ma. Presently it serves as a logical step before con- 
ventional filtration surgery in selected medically 
uncontrolled patients, although there is a growing 
body of evidence that it may be appropriate as the 
initial form of therapy in open-angle glaucoma. AI- 





Abrams DA, Robin AL, Pollack IP, et al: The safety and 
efficacy of topical 1% ALO- (p-aminoclonidine hydro- 
chloride) in normal volunteers. Arch Ophlhalmol 105: 
1205-1207, 1987 
Alvarado JA: Laser photocoagulation for glaucoma re- 
search and therapy. Arch Ophthalmol102: 1604-1605, 1984 
Barnes RJ, Wilensky JT Follow-up data on low-dose tra- 
beculoplasty (abstr). IrmeJt Ophlhalmol Vis Sci (supp1)28:272, 
1987 
Bergea B: Some factors affecting the intraocular pressure 
reduction after argon laser trabeculoplasty in open angle 
glaucoma. Acta Ophthalmof 62:696-704, 1984 
Bergea B: IntraocuIar pressure reduction after argon laser 
trabeculoplasty in open-angle glaucoma. A two-year fol- 
low-up. Acta Ophlhalmol 64:401-406, 1986 
Bishop KI, Krupin ‘I’, Feill ME, et al: Bilateral argon laser 
trabeculoplasty in primary open-angle glaucoma. Am J 
Ophlhalmol 107:591-595, 1989 
Blondeau P, Roberge JF, Asselin Y: Long-term results of 
low power, long duration laser trabeculoplasty. AmJ Oph- 
thalmol 104:339-342, 1987 
Bonney CH, Gaasterland DE, Rodrigues MM, et al: Short- 
term effects of Q-switched ruby laser on monkey anterior 
chamber angle. Inwsl Ophthalmol Vis Sci 22:3 1 O-3 18, 1982 
Brooks AMV, Gillies WE: Do any factors predict a favor- 
able response to laser trabeculoplasty? Ausf Ophlhnlmol 
12:149-153, 1984 
Brown RH, Stewart RH. Lynch MO, et al: ALO- re- 
duces the intraocular pressure elevation after interior seg- 
ment laser surgery. Ophthaltnology 95:378-384, 1988 
Brown SVL, Thomas JV, Budenz DL, et al: Effect of cata- 
ract surgery on intraocular pressure reduction obtained 
with laser trabeculoplasty. Am J Ophthalmol 100:373-376, 
1985 
Brown SVL, Thomas JV, Simmons RJ: Laser trabeculo- 
plasty retreatment. AnJ Ophlhnlmol 99~8-10, 1985 
Brubaker RF, Liesegang TJ: Effect of trabecular photoco- 
agulation on the aqueous humor dynamics of the human 
eye. Am J Ophthalmol 96: 139-147, 1983 
Bylsma SB, Samples JR, Acott ‘IS, Van Buskirk EM: Re- 
population of the trabecular meshwork after argon laser 
trabeculoplasty (abstract). Invcsl Ophfholmol Vu Sci (sz~pp/) 
29:129, 1988 
Bylsma SB, Samples JR, Acott I‘S, Van Buskirk EM: I‘ra- 
becular cell division after argon laser trabeculoplasty. Arch 
OphUudmol I O6:544-547, 1988 
16. Coleman A, Higginbotham E, Yue B, Zou X: The effect of 
























argon laser trabeculoplasty on the distribution of fibronec- 
tin in the trabecular meshwork. Inrjrst Ophthnlmol Vis .%I 
(supp1)29:130. 1988 
Dake CL. Bos PJM: Treatment of glaucoma simplex with 
argon laser coagulation of the scleral spur (L.SS.C.). Dot 
Oph~halnrolog~ct1~ 55:41-46, 1983 
Del Priore LV, Robin AL, Pollack IP: Long-term follow-up 
of neodymium:YAG laser angle surgery for open angle 
glaucoma. Opthalmology Y5:277-281, 1988 
De Venecia G, David MD: Diurnal variation of intraocular 
pressure in the normal eye. Arch Ophlhnlmol 69:112-l 14. 
1963 
Dorigo MT, Dora I>, Cecchinato A: Aqueous prostaglandin 
E2 and intraocular pressure after argon laser trabeculo- 
plasty in glaucoma patients pre-treated with topical piroxi- 
cam. In1 J ~‘KS~P Rracl 9:73-7.5. 1987 
Drance SM: The significance of the diurnal tension vari- 
ations in normal and glaucomatous eyes. Arch Oph/hnlmol 
h-1:494-501, 1960 
Eguchi S, Yamachita H, Yamamoto I‘, et al: Methods 01 
argon laser trabeculoplasty. complications and long-term 
follow-up of results. Jpn J Ophthalmol 29: 198-2 11, 1985 
Ellingsen HA, Grant WM: Influence of intraocular pres- 
burr and trabeculectomy on aqueous outflow in enucleated 
monke) eyes. Inrr& Ophlhalmol 10:705-709, 197 I 
Elsas ‘1‘: Primary laser trabeculoplasty a comparison of 50 
spots in 180” and 100 spots in 360” of the trabecular mesh- 
work. Aria Ophlhalmologzca 65:323-325. 1987 
Epstein DL, Melamed S, Puliafito CA, Steinert RF: Neody- 
mium:1’AC; laser trabeculopuncture in open-angle glauco- 
ma. OphtholmolaR; 92:931-937, 1985 
Fazio P. Werner EB, Krupin I‘: A randomized prospective 
study comparing 180” vs 360” argon laser trabeculoplasty 
ill open angle glaucoma. Inr~r\l Ophlhalmol I’L\ Sri (suppl) 
2Yt235, 198X 
Feller DB, Weinreb RN: Breakdown and reestablishment 
of the blood-aqueous barrier with laser trabeculoplast), 
.4rrh Oj&hnlmol 102:537-538, 1984 
Eclhnan RL, Starita RJ, Spaeth GL, Prtyzees EM: Argon 
laser trabeculoplasty following failed trabeculectomy. Oph- 
Ihalmic Surg 15: 195-198. 1984 
Fink AL, Jordan AJ, Lao PN, Fong DA: The therapeutic 
limitations of argon laser trabeculoplasty. TUU/S Am Oph- 
lhnlrnol Sot X3:236-249, 1985 
Forbes M, Bansal RK: Argon laser gonio-photocoagulation 
ofthe trabecular meshwork in open-angle glaucoma. ‘frcrr/\ 
.*lm Ophtholmol Sot 79:257-272, 1981 
Forbes M, Bansal RK: Argon laser gonio-photocoagulation 
ofthe trabecular meshwork in open-angle glaucoma. C&u- 
IIIN1~1 j:lOO-107, 1982 
(;aasterland D, Bonney C: Long-term effects ofQ-switched 
on monkey anterior chamber angle (abstract). Inzlp.~/ Ojph- 
lholmol l’i.\ sci (.wpp/)22: 193, 1982 
(;aasterland DE. Kupfer Cl: Experimental glaucoma in the 
rhesus monkey. Irnv~/ Oph/hnlmol Vi.\ Sri 13:455-457, 1974 
(iallin MA, Obstbaum SA. Asano Y, et al: Laser trabeculo- 
plasty and cataract surgery. Tran Ophthalmol SW UK l@#: 
72-75. 1985 
(Xbert CM, Brown RH, Lynch MC;: The eft‘ect of argon 
laser trabeculoplasty on the rate of filtering surgery. Oph- 
/h&zolo~ 93~362-365, 1986 
C;laucc~n;a Laser Trial Research Group: The Glaucoma La- 
vx ~l‘rial. I. Acute effects of argon laser trabeculoplasty on 
mtraoculat pressure. :lrrh Ophthalmol 107:113.5-l 142, 
19x9 
I‘he Glaucoma Laser ‘l‘rial Research Group: The Glauco- 
ma Laser ~l‘rial (GL’I‘): 2. Results of argon laser trabeculo- 
plasty versus topical medications. Ophfhnlmolo~ 97: 
1403-1413, 1990 
hrilkd 19/:13-1.i. 1987 
Goldberg I: Argon laser trabeculoplasty and the open-an- 
gle glaucoma. ,4x$/ h’Z ,/ Ophthalmol 13:243-248, 1985 
Goldmann DB, Mellin KB: Argon laser trabeculoplasty in 
special forms ofopen-angle glaucoma. Klin Moncl/.sh/Augrn- 
39. (irayson DK, Camras CB, Podos SM, Lustgarden JS: Long- 
term reduction of intraocular pressure after repeat argcm 
laser t rabeculoplasty. Am J Ophthnlmol 106:3 12-32 1, 198X 
40. Greenidge KC, Rodrigues MM, Spaeth GL. et al: Acute 
intraocular pressure elevation after argon laser trabeculo- 
plast) and iridectomy. A clinical pathologic study. Ophlhal- 
rnic Surg 15:105-l 10. 1984 
4 I Greenidge KC, Spaeth GL. Fiol-Silva Z: Ettct of argon 
laser trabeculoplasty on the glaucomatous diurnal curve. 
O+h/halmolog?’ 90:800-803, 1983 
42. Grinich NP, Van Buskirk EM. Samples JR: ‘l‘he eficacy of 
argon laser trabeculoplasty. Oph/hrr/mo/q~ Y-+:X%-X61. 
1987 
43. Gross RL, Wilson RP, Feldman KM: Encapsulated hleh 
after- trabeculectomy: A frequent complication. C:/irllrtl/ 
.S~~TI.\ irl Ophfhnlmology 9(3):2-l 6, 19X7 
44. Hager H: Besondere mikrochirurgischr t:ingriHe. II. 
Erstc Erfahrungen mit dem Argon-Laser-(;erat X00. h’/r)t 
Mon~/th/ Arcgrnhrdkd lh2:437-450, 197X 
45. Heijl A: One- and two-session laser trabeculoplasty. A IXII- 
domiled. prospec-tier stud\. ,-ltlcr O~jhthrr/vw/ h2;715-724. 
19x-I 
46. Heijl A, Bengtsson B: ‘l‘he short-term eftect 01 laser trabec- 
uloplastu on the glaucomatous visual field. A prospective 
study using computerized perimett-\. .lrlrr Ophlhnlmol 62. 
705-713, 19x4 
47. Heuer- DK, Ciressel MG, Parrish RK. et al: ~I‘rabeculectomy 
in aphakic eyes. Ophlhalmology YI: 1045-I 05 I, I !I84 
4X. Higginbotham EJ, Richardson ‘I‘M: Response of exfolia- 
tion glaucoma to lasct- trabeculoplasty. Ur ,/ Oph/hmlmo/ 
70:X37-X39, 1986 
49. Higgins RA: .l‘wo years experience with laser rrabec-ulo- 
plasty. .4/0( :VZ ,/ Ophfhnlmol 13:2:37-24 1. 10X.5 
50. Hitchings R.4: (:ombined dye and argon laser treatmenr 
fin narrow angle glaucoma. 7‘,(//1\ ophlhrrl~llol .soc I :li 
1OJ:52-54. 1984 
3 I. Holmin C. Bauer B: Laser trabeculoplasty in open-angle 
glaucoma: A short-term study using computeri/cd pet-im- 
etry. /Irk (~phtholt~lologitn K?:3:37-34 I. I WI 
5 la.Holmin C, Krakau CEl‘: Trabeculoplastv and 1 isual Geld 
decay: A follow-up study using computerixd perimrtry. 
C:/~U Epc R/s\ ?:I 101-l lo.‘,, 19X-1 
52. Hong i:. Kitazwa Y. ~1‘ anishima I‘: 1 r~tluerwe of argon laser 
treatment of glaucoma on corncal ~ndothelium. ,/ptl ,/ 
Oph/halmol -37:567-674. 19HY 
.?:‘I. HOI-11s DJ, Bellows AR, Hutchinson B’l‘. Allen KC: Argon 
laser trabeculoplasty for open angle glatlcoma. A retro- 
spectibe study of 980 e)es. 7‘r11v\ O~~h/ho/~t~o/ SOC 1 ‘R 103: 
288-295. I9ti3 
54. Hoskins HI), Hetherington J, Minckler 1%. et al: Compli- 
cations of laser traheculoplasty. Ot,hthcrln~nl,,g~ Y/):796-799. 
1983 
5.5. Hot&kiss ML, Robin AL. Pollack IP, Quiglrav HA: Non- 
steloidal anti-inflammatory agent5 after argon laser tra- 
betuloplasty. Ophthalmolr~cq YJ:960-976, 19X-I 
55a.Keiqhtlev S.J, Khaw PI‘, Elkington AK: ‘I‘hr 1”ediction ot 
intraocuiar pressure rise tbllowing argcm laser trahetulo- 
plasty. Qr 1:.577-580, 19X7 
36. Khan KA, I.eclerer CM Jr, \Clloughb> 1.: Argon laser tra- 
beculoplasty in a resident! program. O~~J~//IIII~~I~~ . /trg 17: 
34?-3.50 1986 . 1x 
57. Kitarawa Y, Horie~l‘: Diurnal \,a)-iation ofitltraocular pres- 
sure in primary open-angle glaucoma. .Am ,/ Of,hlhtrlmo/ 
7Y:.557-566, 1975 
5X. Kitadawa ‘L’, Yamamoto -1‘. Shirato S. Eguchi S: The tech- 
nique of argon laser trabeculoplasty and its reslllts. K/irj 
Morral.thl Augtnh~ilkd lK4:274-277, 1984 
.59. Klein HYZ. Shields MB. Ernest J’I‘: .I wo-st.lge argon laser 
trabeculoplasty in open-angle glaucoma. .4v1 / Ophfhrrlmol 
‘19.392-395, 19% 
60. Koss MC. March WF, Nordquist RE, (;hcrr/.hgiher ‘1 : 
Acute intraocular pressure elevation prc~duced by argon 
laser trabrculoplasty in the c~nomolgus monke!. .4rrh 
Ophthnlmt~l 102: 1699-I 7o:i. IO84 






Krasnov MM: Laseropuncture of the anterior chamber an- 
gle in glaucoma. Am J Ophthalmol 75:674-678, 1973 
Krasnov MM: Q-switched laser gonio-puncture. Arch 
Ophthalmol 9237-4 1, 1974 
Krupin T, Kolker AE, Kass MA, Becker B: Intraocular 
pressure the day of argon laser trabeculoplasty in open- 
angle glaucoma. Ophthalmology 91:361-365, 1984 
Krupin T, Patkin R, Kurata FK, et al: Argon laser trabecu- 
loplasty in black and white patients with primary open- 
angle glaucoma. Ophthalmology 93:8 1 l-8 16; 1986 _ 
Lieberman MF, Hoskins HD. Hetherineton 1: Laser tra- 
















Logan P, Burke E, Joyce PD, Eustace P: Laser trabeculo- 
plasty in the pseudo-exfoliation syndrome. Trans Ophthal- 
mol Sot UK 103:586-587, 1983 
Lund OE: Laserbehandlung des Glaukoms. Fortschr Oph- 
thalmol85:583-592, 1988 
Lunde MW: Argon laser trabeculoplasty in pigmentary dis- 
persion syndrome with glaucoma. Am J Ophthalmol 96: 
721-725, 1983 
Lustgarden J, Podos SM, Ritch R, et al: Laser trabeculo- 
plasty, A prospective study of treatment variables. Arch 
Ophthalmol IO2:5 17-5 19, 1984 
Makabe R: Comparison of krypton and argon laser trabec- 
uloplasty. Klin Monatsbl Augenheilkd 189:118-120, 1986 
March WF. Gherezghiher T, Koss M, Nordquist R: Ultra- 
structural and pharmacologic studies on laser-induced 
glaucoma in primates and rabbits. Lasers Surg Med 4: 
329-335, 1984 
Melamed S, Epstein DL: Alterations of aqueous humor 
outflow following argon laser trabeculoplasty in monkeys. 
Br J Ophthalmol 71:776-781, 1987 
Melamed S, Pei J, Epstein DL: Short-term effect of argon 
laser trabeculoplasty in monkeys. Arch Ophthalmol 103: 
1546-1552, 1985 
Melamed S, Pei J, Epstein DL: Delayed response to argon 
laser trabeculoplasty in monkeys. Arch Ophthalmol 104: 
1078-1083, 1986 
Melamed S, Pei J, Puliafito CA, Epstein DA: Q-switched 
Neodymium:YAG laser trabeculopuncture in monkeys. 
Arch Ophthalmol 103:129-133, 1985 
Messner D, Siegel LI, Kass MA, et al: Repeat argon laser 
trabeculoplasty. Am J Ophthalmol 103:113, 1987 
Migdal C, Hichings R: Primary therapy for chronic simple 
glaucoma. The role of argon laser trabeculoplasty. Trans 
Ophthalmol Sot UK 104:62-66, 1985 
Migdal C, Hitchings R: Control of chronic simple glauco- 
ma with primary medical, surgical, and laser treatment. 
Trans Ophthalmol Sot UK 105:653-656, 1986 
Mishima S, Kitazawa Y, Shirato S: Surgical treatment of 







Mishima S, Kitazawa Y, Shirato S: Laser therapy for glau- 
coma. Aust NZ J Ophthalmol 13:225-235, 1985. - 
Moulin F. Haut 1. Abboud E: Trabeculonerforation? Tra- 
beculoretraction>.Trabeculoplasty? Revi’ew of the various 
designations used for laser treatment in primary open- 
angle glaucoma. Ophthalmologica 191:75-83, 1985’ . 
Ofner S, Samnles IR. Van Buskirk EM: Pilocarnine and the 
increase in in;rao&ar pressure after trabeculoplasty. Am J 
Ophthalmol 97:647-649, 1984 
Pappas HR, Berry DP, Paratamian L, et al: Topical indo- 
methacin therapy before argon laser trabeculoplasty. Am J 
Ophthalmol 99:571-575, 1985 
Pederson JE, Gaasterland DE: Laser-induced primate 
glaucoma. I. Progression of cupping. Arch Ophthalmol 102: 
1689-1692, 1984 
85. Perkins TW, Hoskins HD, Hetherington I, et al: Effect of 
Y I 
86. 
argon laser trabeculoplasty on subsequent trabeculectomy 
(abstract). Invest Obhthalmol Vis Sci (su1161)22:252. 1986 
Pohjanpelto P: Argon laser treatment dfthe anterior cham- 
ber angle for increased intraocular pressure. Acta Ophthal- 



























Pohjanpelto P: Late results of laser trabeculoplasty for in- 
creased intraocular pressure. Acta Ophthalmol 61: 
998-1008, 1983 
Pollack lP, Robin AL: Argon laser trabeculoplasty: Its ef- 
fect on the medical control of open-angle glaucoma. Oph- 
thalmic Surg 13:637-643, 1982 
Pollack IP, Robin AL, Sax H: The effect of argon laser 
trabeculoplasty on the medical control of primary open- 
angle glaucoma. Obhthalmoloev 90:785-789. 1983 y - “I 
Quansah FA, Vela MA, Harbin TS Nd:YAG laser to the 
angle in open angle glaucoma (abstract). Invest Ophthalmol 
Vis Sci (supp1)29:234, 1988 
Quigley HA, Hohman RM: Laser energy levels for trabecu- 
lar meshwork damage in the primate eye. Invest Ophthalmol 
Vis Sri 24:1305-1307, 1983 
Radius R, Pederson JE: Laser-induced glaucoma. Il. His- 
topathology. Arch Ophthalmol 102: 1693-I 698, 1984 
Richter CU. Shingleton BJ, Bellows AR, et al: Retreatment 
with argon laser trabeculoplasty. Ophthalmology 94: 
1085-1089, 1987 
Richter CU, Shingleton BJ, Bellows AR, et al: The develop- 
ment of encapsulated filtering blebs. Ophthalmology 95: 
1163-I 168, 1988 
Ritch R: A new lens for argon laser trabeculoplasty. Oph- 
thalmic Surg 16:331-332, 1985 
Ritch R, Podos S: Laser trabeculoplasty in the exfoliation 
syndrome. Bull NY Acad Med 59:339-344, 1983 
Robin AL, Pollack IP: Argon laser trabeculoplasty in secon- 
dary forms of open-angle glaucoma. Arch Ophthalmol IOI: 
382-384, 1983 
Robin AL, Pollack IP: The Q-switched ruby laser in glauco- 
ma. OtrhthalmoloPv 91:366-372. 1984 
Robin’ A, PollacK IO: Q-switched neodymium:YAG laser 
angle surgery in open-angle glaucoma. Arch Ophthalmol 
103:793-795, 1985 
Robin AL, Pollack IP, House B, Enger C: Effects of AL0 
2145 on intraocular pressure following argon laser trabec- 
uloplasty. Arch Ophthalmol 105:646-650, 1987 
Rodrigues MM, Spaeth GL, Donohoo P: Electron micros- 
copy of argon laser therapy in phakic open-angle glauco- 
ma. Ophthalmology 89: 198-2 10, 1982 
Rosenblatt MA, Luntz MH: Intraocular pressure rise after 
argon laser trabeculoplasty. Br J Ophthalmol 71:772-775, 
1987 
Rosenthal AR, Chaudhuri PR, Chiapella AP: Laser trabec- 
uloplasty primary therapy in open-angle glaucoma. Arch 
Ophthalmol 102:699-701, 1984 
Rouhiainen H, Terasvirta M: The laser power needed for 
optimum results in argon laser traceculoplasty. Acta Oph- 
thalmol 6#:254-257, 1986 
Rouhiainen H.J, Terasvirta ME, Tuovinen El: Laser power 
and postoperative intraocular pressure increase in -argon 
laser trabeculonlastv. Arch Obhthalmol 105:1352-1354. 
1 z 
1987 
Rouhiainen HJ, Terasvirta ME, Tuovinen EJ: Peripheral 
anterior synechiae formation after trabeculoplasty. Arch 
Ophthalmol 106:189-191, 1988 
Rouhiainen HJ, Terasvirta ME, Tuovinen EJ: The effect of 
some treatment variables on the results of trabeculoplasty. 
Arch Ophthalmol 106;61 I-614, 1988 
Ruderman JM, Zweig KO, Wilensky JT, Weinreb RN: Ef- 
fects ofcorticosteroid pre-treatment on argon laser trabec- 
uloplasty. Am J Ophthalmol 96:84-89, 1983 
Safran MJ, Robin AL, Pollack IP: Argon laser trabeculo- 
plasty in iounger patients with primavy open-angle glau- 
coma. Am I Ofihthalmol 97:292-295. 1984 
Saposnik is: Argon laser trabeculoplastv in svstemic-ste- 
raid-induced glaucoma. Glaucoma lb:95196, 1’988 
Schrems W, Glaab-Schrems E. Krieelstein GK. Levdacker 
W: Zui Wirkung der Neodym-?AG-Laserbehandlung 
beim Offenwinkel-Glaukom. Fortschr Ophthalmol 82: 
382-384, 1985 
Schrems W, Hofmann G, Krieglstein GK: Therapie des 
Offenwinkelglaukoms mit dem Argon-und-Neodym-YAG- 

























Laser. Fortschr Ophthalmol 85: 119-I 23, 1988 
Schultz JS, Werner EB, Krupin ‘I‘, et al: Intraocular pres- 
sure and visual field defects after argon laser trabeculo- 
plasty in chronic open-angle glaucoma. Ophthalmology 94: 
553-557, 1987 
Schwart? AL, Anderson DR: Trabecular surgery. ,4rch 
Ophthnlmol 92: 134-I 38, 1974 
Schwartz AL, Kopelman J: Four year experience with ar- 
gon laser trabecular surgery in uncontrolled open-angle 
glaucoma. Ophthalmology WI:77 l-779, 1983 
Schwartz AL, Love DC, Schwartz MA: Long-term follow- 
up of argon laser trabeculoplasty for uncontrolled glauro- 
ma. Arch Ophthalmol 103:1482-1484, 1985 
Schwartz AL. Perman Kl, Whitten M: Argon laser trabecu- 
loplasty in progressive low-tension glaucoma. Ann Oghthnl- 
mol 16:560-566, 1984 
S&wart/. AL, Whitten ME, Bleiman B, Martin D: Argon 
laser trabeculoplasty in uncontrolled phakic open-angle 
glaucoma. Ophthalmology 88:203-212, 1981 
Schwartz LW, Spaeth GL, Traverso C, Greenidge KC: 
Variation oftechniques on the results ofargon laser trabec- 
uloplasty. Ophthalmology 90:781-784, 1983 
Sharpe ED, Simmons RJ: Argon laser trabeculoplasty as a 
means of decreasing intraocular pressure from “normal” 
levels in glaucomatous eyes. Am J Ophthnlmol 99:704-707. 
19% 
Sherwood MB, Svedbergh B: Argon laser trabeculoplasty 
in exfoliation syndrome. Hr J Ophthalmol69:886-890, 1985 
Shingleton RI, Richter CU, Bellows AR, et al: Long-term 
effic&y of argon laser-trabeculoplasty. Ophthalmol@y 94: 
1513-1518, 1987 
Shirato S, Yamamoto T. Kitazawa Y: Argon laser trabecu- 
Ioplasty in open-angle glaucoma. Jpn ‘j Ophthalmol 26: 
374-386. 1982 
Simmons RJ, Kimbrough RL, Belcher CD, Dulit RA: Laser- 
gonioplasty for special problems in angle closure glauco- 
ma, in SympoGum on Gluucomn: Transactions of the New Or- 
/emn.\ AcdPmp ?/‘Ophthalmolog?. St. Louis, CV Mosby, 198 I , 
pp 220-23.5 
Singh M, Kaur B: Argon laser trabeculoplasty in Asian 
eyes. fnt Ophthalmol lO:l61-165, 1987 
Smith J: Argon laser trabeculoplasty: comparison of bi- 
chromatic and monochromatic wavelengths. Ophthalmology 
91.355-360. 1984 
Spaeth CL: The effect of change in IOP on the natural 
history of glaucoma: Lowering intraocular pressure in 
glaucoma can result in improvement of visual fields. Trany 
Ophthnlmol Soc UK 104:236-264, 1985 
Spaeth GL, Fellman RI., Starita RJ, Poryzees EM: Argon 
laser trabeculoplasty in the treatment of secondary glauco- 
ma. Trony ,4m Ophthalmol Sor UK 81:325-332, 1983 
Spurn) RC, Lederer CM Jr: Krypton laser trabeculoplasty 
A clinical report. Arch Ophthalmol 102:1626-1628, 1984 
Starita RJ, Fellman RL. Spaeth GL, Poryzees E: The effect 
of repeating full-circumference argon laser trabeculo- 
plasty. Ophthalmic Surg 15:41L43, 1984 
Starita RI, Rodrigues MM, Fellman RL, Spaeth CL: Histo- 
pathologic verification of position of lase; burns in argon 
laser trabeculoplastv. Obhthnlmic SUW 15:854-858. 1984 
Surton GE, Chtiste&el; (;R, Record; RE: Trabec~lotomv 
with continuous argon laser. Tram Ophthalmol Sor L/h’ 
IOI:llX-120, 1981 
I‘eichmann 1, Teichmann KD, Fechner PR: Glaucoma op- 
eration with the argon laser. Eye Ear Nose Thronf Mouth 
55:“09-211, 1976 
I‘homas JV: Laser trabeculoplasty, in Belcher CD,Thomas 
IV, Simmons RJ (eds): Photocoagulation in Gluucom~ and 
:intrrior Segment Diseas Baltimore, Williams & Wilkins, pp 
61-86, 1984 
‘I‘homas JV, El-Mofty A, Handy E, Simmons RJ: Argon 
laser trabeculoplasty as initial therapy for glaucoma. Arch 
Ophthalmol 102:702-703, 1984 
‘I‘homas JV, Simmons RJ, Belcher CD: Argon laser trabec- 










ogy 89:187-197, 1982 
Thomas JV, Simmons RJ, Belcher CD: Complications of 
argon laser trabeculoplasty. Glaucoma 4:50-52, 1982 
Thoming C, Van Buskirk EM, Samples 1R: The cornea1 
endothecum after laser treatment ‘for glaucoma. ,4m J 
Obhthalmol 103:518-522. 1987 
&ho U, Zauberman fi: Argon laser application to the 
angle structures in rhe glaucomas. ,4rrh ~phthalmol W: 
61-64, 1976 
Traverse C, Cohen EJ, Groden LR. et al: Central cornea1 
endothelial cell density after argon laser trabeculoplasty. 
4rch Ophthalmol 102:1322-1324, 1984 
I‘raverso CE, Greenidge KC, Spaeth CL: Formation of 
peripheral anterior synechiae following argon laser trabec- 
uloplasty. Arch Ophthalmol 102:861-863. 1984 
I‘raverso CE, Roland0 M, Calabria G, Dolci A: Eye param- 
eters influencing the results of argon laser trabeculoplasty 
in primary open angle glaucoma. Ophthnlmologiro 194: 
174-180, 1987 
l‘raverso CE, Spaeth CL, Starita RJ, Fellman RL, et al: 
Factors affecting the results of argon laser trabeculoplasty 
in open angle glaucoma. Ophthalmzc Surg 17:554-559, 19X6 
Tuulonen A: Laser trabeculoplasty as primary therapy in 
chronic open angle glaucoma. Artn Ophthalmolh2: I50- 155. 
1984 
Tuulonen A: The effect of topical indomethacin on acute 
pressure elevation oflaser trabeculoplasty in capsular glau- 
coma. Acta Ophthalmol 63:245-249, 1985 
145a.Tuulonen .4, Airaksinen PI, Kuulasmaa K: Factors influ- 
encing the outcome of laser trabeculoplasty. ,4mJ Ophthnl- 
















Tuulonen A, Kopponen J, Alanko HI, Airaksinen PJ: Laser 
trabeculoplasty versus medication treatment as primary 
therapy for glaucoma. Actn Ophthnlmologicn 67:275-2H0, 
1989 
‘l‘uulonen A, Niva AK, Alanko HI: A controlled iive-year 
follow-up study of laser trabeculoplasty as primary therapy 
for open-angle glaucoma. .4m J Ophthnlmol lO4:334-33X, 
I987 
Van Buskirk EM: Pathophysiology oflaser trabeculoplasty. 
Surer Ophthalmol 33:264-272, 1989 
Van Buskirk EM, Pond V, Rosenquist RC, Acott ‘I’S: Argon 
laser trabeculoplasty. Studies of mechanism of action. Oph- 
thnlmoloQ 91;1005-1010, 1984 
Van Meter WS, Allen RC, Waring GO, Stulting D: Laser 
trabeculoplasty for glaucoma in aphakic and pseudophakic 
eyes after penetrating keratoplasty. ,4rrh Ophthnlmol 106: 
1X5-188. 1988 
Watson PG, Allen ED, Graham CM, et al: Argon laser tra- 
beculoplasty or trabeculectomy: a prospectiive randomized 
block study. Trans Ophthalmol Sor UK 104;55-61, 1985 
Watson PC;, Grierson 1: The place of trabeculectomy in the 
treatment of glaucoma. Ophthalmology 88: 175-l 96. 1981 
Weber PA, Burton GD, Epitrokoubs AT: Laser trabeculo- 
plasty retreatment. Ophthalmic Surg X1:7092-7096. 1989 
Weinreb RN, Robin AL, Baerveldt G, et al: Flurbiprofen 
pretreatment in argon laser trabeculoplasty ti)r primary 
open-angle glaucoma. At-& Ophthalmol 10-3: 1629-1632. 
1984 
Weinreb RN. Kuderman J, Juster R. Wilensky JT: Influ- 
encc of the number of laser burns administered on the 
early results of argon laser trabeculoplasty. .4m,/ Ophthnlmol 
95:287-292. 1983 
Weinreb RN, Ruderman J, Juster R, Zweig K: Immediate 
intraocular pressure response to argon laser trabeculo- 
plasty. Am J Ophthalmol 95:279-286, 1983 
Weinreb RN. Wilensky JT: Clinical aspects of argon laser 
trabeculoplasty. Int Ophthalmol Clin 20:79-96. 1984 
Werner EB, Drance SM, Schulzer M: Trabeculectomy and 
the progression of glaucomatous visual field loss. :lrch 
Ophthnlmol Y5:1374-1377, 1977 
Wit kham MC, Worthen DM: Argon laser trabeculoplasty: 
long-term follow-up. Ophthalmolog?, 86;495-503, 1979 
Wickham MG. Worthen DM. Binder PS: Phvsiological ef- 
428 Surv Ophthalmol 35 (6) May-June 1991 REISS ET AL 
161. 
B. Perimetry 











fects of laser trabeculotomy in rhesus monkey rats. Inz~esl 
Ophthalmol Vi.s Sci 16:624-628, 1977 
Wilensky JT: Laser trabeculoplasty: technique, in Wilensky 
JT (ed): Laser therapy in Glaucoma. East Norwalk, Connecti- 
cut, Appleton-Century-Crofts, pp 18-19, 1985 
Wilensky JT, Siegel H: Juvenile glaucoma, in Shields MB, 
Pollock IP, Kolker AE (eds): Perspectives in Glaucoma. Thor- 
ofare NJ, Slack, 1988, pp 253-260 
Wilensky IT, Iampol LM: Laser therapy for open angle 
glaucoma: Opkhaimology 88:2 13-2 17, 198 1 _ _ 
Wilenskv IT. Weinreb RN: Low dose trabeculoolastv. Am I 
Ophthalkoi !?5:423--126, 1983 
. I ., 
Wilensky JT, Weinreb RN: Early and late failures of argon 
laser trabeculoplasty. Arch Ophthalmol 101:895-897, 1983 
Wise JB: Long-term control of adult open-angle glaucoma 
by argon laser treatment. Ophthalmology 88: 197-202, 198 1 
Wise JB: Glaucoma treatment by trabecular tightening 
with the argon laser. Int Ophthalmol Clin 21:69-78, 1981 
Wise JB: Errors in laser spot size in laser trabeculoplasty. 
Ophthalmotog?, 91:186-190, 1984 
Wise JB: Management of the glaucomas with argon laser 
(laser trabeculoplasty), in Boyd FG (ed): Highlights oJOph- 
thalmology, 1985 
Wise JB: Ten year results of laser trabeculoplasty. Does the 
laser avoid glaucoma surgery or merely defeat it? Eye 
1:45-50, 1987 
Wise JB, Witter SL: Argon laser therapy for open-angle 
glaucoma: A pilot study. Arch Ophthalmol97:3 19-322, 1979 
Worthen DM, Wickham MG: Laser trabeculotomy in mon- 
kevs. Invest Ophthalmol Vu Sci 12:707-711, 1973 
W&then DM*, Wickham MC: Argon laser trabeculotomy. 
Trans Am Acad Obhthalmol Otolamrwol 78:371-375, 1974 
Yablonski ME, Cook DJ, Gray Jy A fluorophotometric 
study of the effect of argon laser trabeculoplasty on aque- 
ous humor dynamics. Am J Ophthalmol 99:579-582, 1985 
Zborowski L, Ritch R, Podos S, Boas R: Prognostic features 
in laser trabeculoplasty. Acta Ophthalmol62:142-149, 1984 
C. Pigmentation 
D. Preoperative pressure 
E. Results in the fellow eye 
F. Stage of glaucoma 










-Primary open-angle glaucoma 
Pigmentary and exfoliation glaucoma 















A. Pressure elevation 
B. Loss of central island of vision 
C. Peripheral anterior synechiae 
D. Uveitis 
E. Hyphema 
F. Cornea1 sequelae 
G. Syncope 
175. 
H. Effect on future filtration surgery 
VIII. Retreatment 
IX. Ongoing studies 
A. ALT as a primary treatment 
B. ALT vs filtering surgery 
X. Recommendations for treatment 
A. Treatment parameters 
B. Patient management at the time of treatment 
C. Case selection 








Theories regarding the mechanism of action of 
argon laser trabeculoplasty 
Technique 
A. Proportion of the angle treated 
B. Location of burns 
C. Energy density 
D. Laser Wavelength 
Results 
A. Intraocular pressure 
1. Effect on diurnal curves 
2. Reduction in antiglaucoma medications 
3. Duration of effect 
This work was supported in part by grant EY 04634 (Dr. 
Wilensky), EY 06832-3 (Dr. Higginbotham) and a depart- 
mental core grant EY 0 1792 from the National Institutes of 
Health, Bethesda, Maryland. 
Reprint address: Jocob T. Wilensky, M.D., U.I.C. Eye 
Center, Dept. of Ophthalmology, 1855 W. Taylor - Rm. 
2.78, Chicago, IL 60612. 
